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Abstract 
 
Fungi are among the most prolific producers of secondary metabolites, many of which have 
huge utility for society as various anti-infective and anticancer drugs. The genes encoding 
these secondary metabolites are arranged in continuous biosynthetic gene clusters (BGCs). 
Each fungus can have tens of different BGCs in its genome, possessing the ability to produce 
a multitude of secondary metabolites with potential for medical utility. However, most of the 
BGCs are silent under standard laboratory conditions, packaged in heterochromatin, 
inaccessible for transcription. To activate these clusters the heterochromatin must be 
converted to euchromatin, the transcription accessible form. The addition of small molecule 
epigenetic modifiers, inhibiting the activity of transcription repressive epigenetic enzymes, 
have been proven to effectively induce secondary metabolism in many fungi. As this approach 
does not require genetic manipulation, it is potentially applicable to a broad range of fungi, 
recalcitrant to genetic manipulation. This method could therefore have the potential for 
implementation. the high-throughput screening of microorganisms at Marbio. 
In this thesis, the method of manipulating the epigenetic machinery of marine filamentous 
fungi by the application of epigenetic modifiers 5-azacytidine, SBHA, and nicotinamide were 
employed as a means for inducing activation of biosynthetic gene clusters. This is the first time 
epigenetic modifiers have been applied to any microbial cultures at Marbio. The fungi 
investigated were cultivated in solid and liquid media with added epigenetic inhibitors in 
different combinations to study the effects of the modifiers on the fungi. The fungal cultures 
were subsequently extracted and subjected to bioactivity testing. The bioactivity screening 
revealed that epigenetic modifiers did not induce the production of bioactive secondary 
metabolites in detectable amounts. However, SBHA was found to alter colony morphology 
and pigmentation in some cultures, indicating that these fungi are accessible for epigenetic 
manipulation by HDAC inhibitors. Increased concentrations or applications of more potent 
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1 Introduction 
1.1 Secondary metabolites for drug discovery 
Secondary metabolites are compounds of low molecular weight with restricted taxonomic 
distribution. The term natural product (NP) is often used as a synonym for secondary 
metabolites of natural origin. The most prominent producers of secondary metabolites are 
microorganisms such as bacteria and fungi(Hutchings et al., 2019), where their primary 
function is to enhance the producing organism’s fitness and chance of survival by repelling or 
attracting other organisms (Hanson, 2003; McMurry, 2009). These compounds are also widely 
recognized to frequently exhibit activities of high medical utility such as anti-infective, 
immunosuppressive and anticancer properties. (Keller et al., 2005; Winter et al., 2011; Zerikly 
& Challis, 2009). Therefore over half of all drugs are secondary metabolites of natural origin 
or based on such compounds (Montaser & Lunesch, 2011). Despite this, the research into 
secondary metabolites has diminished during the last two decades due to technical barriers 
and high rediscovery rate. However, in the era of genomics secondary metabolites are 
regaining attention. New genomics approaches have revealed that the potential of secondary 
metabolite production, in fungi especially, is much larger than formerly believed and technical 
advancements are making secondary metabolites increasingly accessible (Harvey et al., 2015; 
Koehn & Carter, 2005). 
1.1.1 Potential of marine fungi  
There is a high abundance of species within the fungal kingdom with unique and unusual 
biochemical pathways producing secondary metabolites and enzymes of high pharmaceutical 
utility such as penicillin, cyclosporin and aflatoxins (Keller et al., 2005). The first systematic 
study of fungal secondary metabolites started in 1922, and the following discovery of penicillin 
in 1928 led to a widespread interest in fungal metabolites (Fleming, 1929). Since then the 
screening for fungal secondary metabolites has continued unabated and thousands of 
compounds possessing antibacterial, antifungal, antiprotozoal, antiparasitic anti-insect, 
antivirus and anticancer activity have been identified (Keller et al., 2005). 
Terrestrial fungi have been studied and utilized thoroughly for the last 50 years yielding 
thousands of fungal secondary metabolites with enormous therapeutic value (Aly et al., 2011), 
while marine fungi have just recently started to gain the same attention in the wake of the 
increasing rediscovery rate of already known compounds from terrestrial sources. Due to their 
harsh environment, marine species have had to evolve specialized mechanisms to survive in 
terms of light, salinity and pressure. This is reflected by the multitude of compounds produced 
by marine species to protect themselves from biotic and abiotic stresses, multiple compounds 
which has no terrestrial analogues (Jaspars et al., 2015). 
Marine fungi are a highly diverse taxonomic group and inhabits a huge variety of marine 
habitats, such as sea water, corals, algae and marine sediment. They have numerus ecological 
roles in their habitats, including degradation of organic material, parasitic and mutualistic 
interactions with other marine organisms such as algae and animals, and some are involved 
in denitrifications processes in marine sediments (Zhang et al., 2015). Marine fungi are often 
divided into two groups, obligate marine fungi and facultative marine fungi. While facultative 
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marine fungi are able to grow and sporulate in both marine, freshwater and terrestrial 
environments, obligate marine fungi grow and sporulate exclusively in marine habitats (Pang 
et al., 2016).  
The number of new 
compounds identified 
from marine fungi has 
increased significantly 
recent years with an 
increase of 38% from 
2017 to 2018 (figure 1). 
The increase in overall 
discovery rate during 
the last three years is 
85%. If this discovery 
rate continues, fungi  
are predicted to exceed 
cnidarians as second 
most prolific source of 
marine natural products in 2021 and overtake the status as most prolific source of new marine 
natural products from sponges in 2024 (Carroll et al., 2020). 
1.1.2 Types of secondary metabolites 
There is no rigid classification of secondary metabolites as their great diversity in terms of 
structure, function and biosynthetic makes them hard to put in confined categories. However, 
most can be grouped into the three chemical categories: polyketides (derived from acyl-CoA), 
terpenes (derived from acyl-CoA) and small peptides (derived from amino acids) (McMurry, 
2009). In addition there are also hybrid molecules such as polyketide-terpenes, non-ribosomal 
peptide-polyketides and peptide-fatty acids (Keller, 2019).   
1) Terpenes are the largest and most diverse group of secondary metabolites. They are made 
up of isoprene units that are combined in a linear or cyclic structure that are saturated or 
unsaturated. Terpenes vary greatly in structure, with many structures seemingly unrelated. 
This great diversity is likely a result of the many enzymatic modifications employed such as 
alkylation, cyclization, decarboxylation, glycosylation and redox reactions (Daley et al., 2017; 
Gershenzon & Dudareva, 2007). 2) Polyketides are built by a stepwise condensation of acyl 
units using carbon atoms from methyl and carboxyl groups as acetate building blocks. 
(McMurry, 2009). The great number of possible reductions, iterations, type of extender units 
and possible cyclization of the polyketide chain make them a highly diverse group of 
compounds (Daley et al., 2017). 3) Peptides functioning as secondary metabolites can be 
divided into two classes, the (natural) ribosomal synthesized peptides, and the non-
ribosomally synthesized peptides formed by both proteinogenic and nonproteinogenic amino 
acids by non-ribosomal peptide synthases. While the peptides directly translated from RNA 
are present in all organisms, non-ribosomal peptides are more restricted to bacteria and fungi 
(Daley et al., 2017; Jenssen et al., 2006; McMurry, 2009).  
Figure 1 - Trends in discovery of new marine secondary metabolites from 2014 
to 2018 (Carroll et al., 2020). 
 
   3 
1.1.3 Biosynthesis of secondary metabolites 
In fungi the genes involved in the production of secondary metabolites are grouped together 
in a continuous manner as biosynthetic gene clusters (BGCs) (figure 2) in the sub-telomeric 
regions of the chromosomes (Pfannenstiel & Keller, 2019). The synthesis of a secondary 
metabolite is a multistep process and involves 1) one or more core enzymes, these are the 
chemical class-defining synthase and/or synthetase (e.g. terpene synthase (TS), terpene 
cyclase (TC), polyketide synthase (PKS), and/or non-ribosomal peptide synthetase (NRPS) that 
utilizes a primary metabolite to form the backbone of the secondary metabolite, also known 
as the chemical scaffold. 2) Next tailoring enzymes can modify the carbon backbone further 
(e.g. methyltransferase, p450 monooxygenase, hydroxylase and/or epimerase). 3) Some BGCs 
also encode a cluster-specific transcription factor that upregulate the transcription of the 
other genes in the cluster. 4) If the BGC generate a compound that can be harmful to the 
producing organism the cluster might contain protective genes to minimize the damages. The 
four main types of in-cluster self-protection genes are efflux transporters (e.g. GliA, an efflux 
pump important for the resistance to gliotoxin (Dolan et al., 2015)); cellular BGC intermediate 
transporters (e.g. CefM which translocates the cephalosporin C intermediate penicillin N from 
a microbody to the cytosol, where it is transformed to the end product (Teijeira et al., 2009)); 
detoxifying enzymes that modifies the chemical structure of the finished secondary 
metabolite to reduce target-binding properties and lower affinity to the target protein (e.g. 
the oxidoreductase GliT modifies gliotoxin structure to less-toxic molecule (Dolan et al., 2015; 
Scharf et al., 2010)); lastly the cluster can contain duplicated and resistant copies of the target 
protein (e.g. the lovastatin BGC contains an extra copy of its target protein 3-hydroxy-3-
methylglutaryl-CoA (Abe et al., 2002)). 5) BGCs can also have several incongruous genes with 
hypothetical functions that are not obviously involved in the synthesis of the secondary 
metabolite nor the protection from it, which functions are not fully understood (Keller, 2015, 
2019). 
 
Figure 2 - Schematic overview of the general organization of a biosynthetic gene cluster (Keller, 2019). 
1.2 Connecting biosynthetic gene clusters and secondary 
metabolites 
Despite the great diversity of secondary metabolite chemical scaffolds, the biosynthetic 
principles for most secondary metabolites are highly conserved. Certain collections of enzyme 
families are often and very specifically associated with the biosynthesis of specific categories 
of secondary metabolites. Thus, the sequence information of these biosynthetic gene families 
can be utilized to screen genomes of the biosynthetic gene clusters they are associated with 
(Dimova et al., 2018; Weber & Kim, 2016).The clustering of the genes combined with the 
conserved sequences of synthases such as PKS (polyketide synthase) and synthetases such as 
NRPS (non-ribosomal peptide synthetase) has enabled the development of algorithms able to 
predict the number of BGCs in any sequenced genome. This innovation led to the realization 
that many of the acknowledged drug producing microorganisms actually have the genetic 
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predisposition for producing dozens of more secondary metabolites than they are already 
known to produce (Keller, 2019; Keller et al., 2005; Pfannenstiel & Keller, 2019). 
The recognition that microorganisms has much higher genetic predisposition for synthesis of 
secondary metabolites than first assumed came with the complete sequencing of the model 
organism Streptomyces coelicolor by Bentley et al. in 2002. S. coelicolor had already been 
found to possess five BGCs, but the whole genome analysis revealed 18 additionally clusters 
(Bentley et al., 2002; Rigali et al., 2018). This marked as a landmark event that influenced the 
scientific community on how immense the reservoir of still unknown microbial secondary 
metabolites might be. Several other actinobacteria have now been whole genome sequenced 
and screened for BGCs, and Streptomyces bingchenggensis and Streptomyces rapamycinicus 
with 54 and 51 clusters respectively, are the current most “gifted” actinobacteria. However, 
an even higher potential have been found in filamentous fungi (Baranasic et al., 2013; Rigali 
et al., 2018; X. J. Wang et al., 2010).  
An analysis of 19 Aspergillus genomes by de Vries et al. found a range of 21-66 BGCs in each 
species (de Vries et al., 2017). Some species, such as Aspergillus westerdijkiae, have been 
predicted by antiSMASH to contain 88 BGCs (Han et al., 2016). Considering it is estimated that 
there are 2.2 to 3.8 million fungal species in the world and only about 120 000 species are 
considered well described, the potential for new discoveries is immense (Hawksworth & 
Lücking, 2017). Though this is a huge number, the majority of BGCs are either cryptic or 
expressed at a level too low to detect in standard laboratory culture conditions. This is also 
the case for most other gifted microorganisms as well (Pfannenstiel & Keller, 2019). 
Secondary metabolite production is tightly regulated in microbes due to the high energy 
requirement for the production of these complex molecules due to the many enzymatic steps 
involved. This often makes it very hard to induce the activation of silent BGCs as the 
complexity of the natural induction is hard to mimic in the laboratory (Chianga et al., 2009). 
However, multiple strategies have been established for inducing the expression of BGCs and 
identifying the produced secondary metabolites. The increasing number of whole genome 
sequenced organisms is leading to an emerging number of BGCs identified. In the next 
sections follows a short introduction to some approaches for studying secondary metabolites 
from active BGCs, approaches for identifying associated BGCs of characterized secondary 
metabolites and strategies for activating silent BGCs.   
1.2.1 Strategies for identifying the secondary metabolites produced by 
active BGCs  
1.2.1.1 Mass Spectrometry 
Mass spectrometry (MS) is an analytical technique that can be applied to study the molecular 
composition of biological samples, determine elemental composition, and predict some 
molecular structures (Watson & Sparkman, 2007). It works by ionizing a net charge on the 
analyze injected and subsequently sorting the ions based on their mass-to-charge ratio (m/z). 
A mass spectrometer consists of an ion source, a mass analyzer that measures the m/z of the 
ionized analytes, and a detector that records the number of ions at each m/z value. 
Electrospray ionization (ESI) is one of the techniques for volatizing and ionizing analytes, and 
the best suited for analysis of complex samples as it covers a broad area of compouds in terms 
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of size and polarity. ESI ionizes analytes out of a solution and is therefore readily applicable 
for analysis of liquid samples, and thus will be applied in this thesis. The quadrupole time-of-
flight (qTOF) will be applied as the mass analyzer. The TOF analyzer has high sensitivity, 
resolution and mass accuracy. In the analyzer, the ions are accelerated to a high kinetic energy 
and separated along the flight tube based on their different velocities. A collision cell is placed 
between a quadrupole mass filter and a TOF mass analyzer. Ions of specific m/z are selected 
in the TOF mass analyzer, then fragmented in the collision cell. The ions are reversed in a 
reflector before impinging on a detector, that amplifies and records the arriving ions 
(Aebersold & Mann, 2003; Covington et al., 2017). 
MS predictions are made on the compounds ability to ionize. Neutral or poorly ionizing 
compounds are therefore invisible in MS, and the number of detectable compounds thus 
depend the ionization source and conditions applied (Covington et al., 2017). 
1.2.1.2 Gene deletion/disruption 
Once a secondary metabolite has been identified by mass spectrometry it can be linked to its 
producing BGC by gene deletion or disruption of core genes and a following metabolite 
profiling. The comparison of the chemical spectra of the reference strain to the deletion 
mutant should reveal MS signals absent in the deletion mutant, indicating the missing signal 
represent the relevant secondary metabolite (Kjærbølling et al., 2019; Sanchez et al., 2011).  
The gene deletion strategy can be further sophisticated by the generation of deletion libraries 
focusing on one BGC. The libraries can then be screened for the absence of the compound of 
interest, and the genes involved in the synthesis of the secondary metabolite can thereby be 
identified (Kjærbølling et al., 2018). 
1.2.2 In silico strategies for identifying the associated BGCs of identified 
secondary metabolites by whole genome sequences 
One can also connect secondary metabolite and BGCs in the opposite direction by identifying 
a BGC starting from a known secondary metabolite. There are several methods for making this 
connection and the most suiting approach depends on the acquired information/knowledge 
of the specific secondary metabolite. The three main approaches are 1) Homology search; 
identification of the BGC producing a characterized compound by using the BGC of a 
homologous compound as query for a genome search of the homologues BGC. 2) Retro 
biosynthesis; prediction of the enzymatic activities needed to form a compound based on its 
composition and side chains, and subsequent genome search for enzymes of fairly close 
proximity that possess these activities. And 3) Comparative genomics; the BGC for a secondary 
metabolite can be identified by comparing the genomes of organisms producing that 
compound looking for common clusters and checking close related non-producing species for 
the lack of those clusters (Kjærbølling et al., 2019). 
1.2.3 Bioinformatic tools for studying secondary metabolites and BGCs 
The pipeline antibiotics and Secondary Metabolite Analysis SHell (antiSMASH) is currently the 
most comprehensive software for screening of microbial genomes for BGCs (Blin et al., 2019). 
In addition to providing BGC identification antiSMASH also includes detailed annotation of 
domain structures of modular NRPS and PKS, substrate prediction, pathways, whole genome 
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metabolic modelling and comparative genomics tools for identifying conserved sub-clusters  
that synthesize building-blocks, homologues BGCs in other sequenced genomes and the 
Minimum Information about a Biosynthetic Gene cluster (MIBiG) data standard (Weber & Kim, 
2016). 
1.2.4 Strategies for activating silent BGCs 
1.2.4.1 OSMAC 
The OSMAC (One Strain Many Compounds) approach was introduced by (Bode et al., 2002) as 
a method for inducing the activation of secondary metabolisms in microorganisms. The 
method aims at inducing activation by systematically altering cultivation parameters such as 
medium composition, pH, temperature, oxygen availability, culture vessel, and enzymatic 
inhibitors present, and can also include co-cultivation with other microorganisms as an 
attempt to try and simulate the natural variations in the fungal environment and mimic the 
natural inducers of the secondary metabolism (Bode et al., 2002; VanderMolen et al., 2013). 
With this approach researchers have managed to uncover some of the hidden metabolic 
potential of fungi and increase the number of expressed BGCs. However, the efficiency of 
OSMAC is low and this approach is simply not sufficient in activating all clusters alone, but the 
combination of OSMAC with e.g. epigenetic modification have showed increased effectivity in 
inducing BGCs (Chianga et al., 2009; Pfannenstiel & Keller, 2019). 
1.2.4.2 Epigenetic modification 
Some BGCs are physically unavailable for transcription as they are “silenced” and highly 
compressed in heterochromatin and hidden away from transcription enzymes. This is due to 
the epigenetic regulation of the fungal genome performed by the epigenetic machinery 
(Pfannenstiel & Keller, 2019). The enzymes constituting this machinery can regulate the 
tightness of the DNA packaging, making the encoded genes more or less available for the 
transcription apparatus. This can be done by either deleting the genes for the epigenetic 
enzymes, responsible for making the DNA packaging denser, or inhibiting their activity by 
supplementing chemical small molecule inhibitors that blocks their enzymatic activity, and 
thus inhibit the formation of heterochromatin. Multiple of the enzymes of the epigenetic 
machinery have been found to be involved in the regulation of secondary metabolism (Seto & 
Yoshida, 2014). The strategy of this approach is therefore to delete or inhibit the action of the 
enzymes that repress transcription of BGCs and thereby have more BGCs accessible for 
transcription (Pfannenstiel & Keller, 2019).  
1.2.4.3 Other approaches for BGC activation 
The deletion or overexpression of the genes for global regulators of secondary metabolism 
have been found to result in the silencing or increased production, respectively, of multiple 
secondary metabolites and theirs BGCs in various Aspergillus spp. (Bayram et al., 2008). Some 
BGCs also have cluster-specific transcription factors, that can be utilized for targeted 
activation of BGCs. Clusters lacking such activators can alternatively be induced by replacing 
all promoters in the BGC to force the expression of the in-cluster genes (Bayram et al., 2008; 
Keller et al., 2005; Kjærbølling et al., 2019; Perrin et al., 2007).  
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Sometimes the BGC of interest is located in a species which is uncultivable, hard to cultivate 
or not easily genetically manipulated. In these cases, heterologous expression strategies can 
be applied to try and study the BGCs of interest in a host organism more responsive and 




Figure 3 - Epigenetic mechanisms (National Institutes of Health, 2018). 
1.3 Epigenetic manipulation  
Epigenetics is the study of heritable phenotypes, such as secondary metabolite production, 
and do not involve modifications to the DNA sequence. Instead of modifying the DNA 
sequence, the proteins constituting the epigenetic machinery alter gene expression by 
manipulating chromatin (Pfannenstiel & Keller, 2019). Epigenetic means "in addition to 
changes in genetic sequence" and the term covers all processes that lead to changes in gene 
activity without changing the DNA sequence. These modifications of gene activity that can be 
transferred to the next generation of cells (Weinhold, 2006). 
Chromatin is a complex of DNA and proteins in the nucleus. It is made up by DNA wounded 
around small proteins called histones to form structural units named nucleosomes (figure 3). 
There are two main types of chromatin – euchromatin, which is loosely packaged, accessible 
DNA that is available for transcription, and heterochromatin, which is densely packaged and 
inaccessible for transcription. The strength of the interaction between the histones and the 
DNA and the density of the DNA packaging can be controlled by modifying the chromatin by 
the placement or removal of epigenetic factors (figure 3) (Pfannenstiel & Keller, 2019). 
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1.3.1 Chromatin modulation 
There is a wide array of epigenetic 
processes that can be applied to modify 
chromatin, these can either be applied 
directly to the DNA, e.g. by adding 
methyl groups to cytosines, or to the 
histone tails (figure 3 
). Histone tails are the main target for 
chromatin regulation of secondary 
metabolism. There are multiple types of 
highly dynamic, reversable 
modifications, known as epigenetic 
factors or post translational 
modifications (PTMs) that can be placed 
on the many residues of the histone tail 
and multiple PTMs that can be placed on 
the same residue. These are 
methylation, acetylation, ubiquitination, 
deamination, phosphorylation, ADP 
ribosylation, sumolyation, and several 
others. Methylation and acetylation are 
the best studied in relation to secondary 
metabolism  (Bannister & Kouzarides, 
2011; Pfannenstiel & Keller, 2019; 
Weinhold, 2006). The current hypothesis 
is that histone PTMs either act as signals 
or binding sites for downstream 
transcriptional processes or act by 
influencing the structure of the local 
chromatin (Pfannenstiel & Keller, 2019).  
The histone modifications are controlled 
and decoded by three types of proteins 
constituting the epigenetic machinery. 
Writers place modifications on histone 
tails, erasers remove modifications, and 
readers recognizes the modifications on 
histone tails and brings writers and/or erasers to the correct genomic loci to act (figure 4). 
Acetyltransferases (HATs) are the writer enzymes that transfer acyl group to specific lysine 
residues of the histone tails from acetyl-CoA. The acetylation of histones is hypothesized to 
neutralize the positive charge of the histone, making the interaction with the negatively 
charged DNA weaker, thus loosen the DNA packaging, making the DNA accessible for 
transcription (Pfannenstiel & Keller, 2019). Deacetylation of histone tails is performed by the 
eraser enzymes, histone deacetylases (HDACs). They increase the positive charge of the 
Figure 4 – Histone tail PTMs and the enzymes regulating them. 
A) Illustration of the histone tails and the many amino acid 
residue that can be targeted for PTMs. B) The proteins 
constituting the epigenetic machinery; writers (green), erasers 
(light blue) and readers (purple), the dark blue dots represents 
PTMs placed on  the histone tails (Pfannenstiel & Keller, 2019).  
Figure 5 – The two main strategies for interfering with chromatin 
regulation. A) the action of an eraser under wild type conditions 
leading to the formation of heterochromatin and the repression 
of transcription. B) eraser gene deletion resulting in no erasing 
of PTMs and genes remaining active in euchromatin 
conformation, accessible for transcription. C) inhibition of 
eraser by small molecule chemical inhibitors resulting in no 
PTMs removed and persistently active genes  (Pfannenstiel & 
Keller, 2019). 
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histones and thereby strengthen the interaction to the negatively charged DNA and repress 
transcription. Histone deacetylases are divided into two families, the zinc depended histone 
deacetylase (HDAC) family and the NAD+ dependent Sir2 regulatory family. There are four 
classes of HDACs. Class; I, II and IV belong to the HDAC family and Class III belongs to the Sir2 
regulatory family (Seto & Yoshida, 2014).  
Methyltransferases are the writer enzymes responsible for methylation of histone tails. In 
contrary to acetylation, which is mostly associated with transcription activation, the effects of 
methylation are more complex and depends on which specific histone tail residue.  In addition, 
residues can be methylated in multiple levels (mono- di- or tri-) with each having specific 
biological effects. These histone methylations can be removed by the erasers histone 
demethylases (Pfannenstiel & Keller, 2019). 
Currently there are two main strategies for interfering with chromatin regulation to activate 
silent BGCs. These are deletion or overexpression of chromatin modifying enzymes or addition 
of small molecule chemical inhibitors to prevent the formation of heterochromatin (figure 5) 
(Pfannenstiel & Keller, 2019).  
1.4 Epigenetic modifiers  
The two major groups of small molecule epigenetic modifiers are the DNA methyltransferase 
(DNMT) inhibitors and the histone deacetylase (HDAC) inhibitors. 
1.4.1 DNA methyltransferase inhibitors 
In contrary to histone methyltransferases, DNA methyltransferases (DNMT) targets DNA 
directly. DNMTs methylate cytosine bases by binding the cytosine, transferring a methyl group 
to C5 from the cofactor S-adenosyl-L-methionine (SAM), producing 5-methylcytosine. the 
DNMT is then released by β-elimination. 5-azacytidine is the most widely used DNMT 
inhibitor. It inhibits DNMT activity by a trapping mechanism. DNMTs bind 5-azacytidine in the 
same manner as cytidine. However, because 5-azacytidine has a nitrogen located at the 5-
position the DNMT is not able to release itself by β -elimination and becomes irreversibly 
covalent bound (figure 6) (Gnyszka et al., 2013; Stresemann & Lyko, 2008). 5-azacytidine has 
been used to identify novel secondary metabolites in several fungal species including  
Cladosporium cladosporioides, Diatrype disciformis (Williams et al., 2008) and Beauveria 
bassiana (Yakasai et al., 2011). 
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Figure 6 - Mechanism of action for DNMT inhibitor 5-azacytidine. A) Mechanism of DNMT for methylation of cytosine 
bases. B) Inhibition of DNMT by 5-azacytidine resulting in trapped enzyme irreversible bound to 5-azacytidine 
(Gnyszka et al., 2013). 
1.4.2 Histone deacetylase inhibitors 
Histone acetylation is associated with transcription activation. Histone deacetylases are 
divided into two families, the zinc depended histone deacetylase (HDAC) family and the NAD+ 
dependent Sir2 regulatory family. There are four classes of HDACs. Class; I, II and IV belong to 
the HDAC family and Class III belongs to the Sir2 regulatory family (Pfannenstiel & Keller, 2019; 
Seto & Yoshida, 2014).  
1.4.2.1 HDAC class I, II and IV – inhibitors 
HDAC inhibitors can be divided into four groups based 
on their chemical structures: hydroxamate, 
benzamide, cyclic peptide and short-chain fatty acid. 
The two hydroxamates Trichostatin A (TSA) and 
suberoylanilide hydroxamic acid (SAHA) are the best 
studied. They bind the HDAC by inserting their long 
aliphatic chain into the catalytical core of the HDAC, 
(consisting of a tubular pocket, the zinc-binding site 
and the active-site residues) with multiple contact 
points to the tubular pocket. There they make 
hydrogen bonds with histidine and tyrosine residues 
located around the zinc ion. At the other end of the TSA 
and SAHA molecules, their aromatic ring group interacts with the residues at the lining of the 
rim of the pocket, thereby locking the inhibitor in the pocket. TSA and SAHA (figure 7) are 
considered pan-HDAC inhibitors capable of inhibiting the activity of both class I, II and IV 
HDACs due to this strong binding (Seto & Yoshida, 2014).  
Figure 7 - Chemical structure of the two 
HDAC inhibitors TSA and SAHA. 
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1.4.2.2 HDAC class III – inhibitors 
Sirtuins are known to perform 
two enzymatic activities: 
histone deacetylase and ADP-
ribosyltransferase, and they 
require an NAD+ cofactor for 
their enzymatic activity. 
The catalytic site of sirtuins is 
located in a cleft between the 
large and small domain of the 
protein. This cleft form a 
protein-tunnel in which the 
substrate can interact with 
NAD+. Sirtuins deacetylate 
lysine residues of histone tails 
by binding NAD+ to the 
acetylated lysine and cleaving 
off nicotinamide and thereafter 
removal of O-acetyl-ADP-ribose 
by water resulting in the 
deacetylated lysine residue and 
2'-O-acetyl-ADP-ribose (figure 
8) (Seto & Yoshida, 2014). 
Nicotinamide is widely used as a sirtuins inhibitor. Because it is a by-product of sirtuin 
deacetylase activity, and thus a physiological inhibitor it requires high concentrations to shift 
the direction of the reaction to decease the gene silencing. Some sirtuin specific inhibitors 
have also been discovered, such as sirtinol, splitomicin and sodium butyrate, however, their 
specific mechanisms for inhibiting sirtuin activity are not yet characterized (Seto & Yoshida, 
2014). 
1.4.3 Studies of BGC activation by the application of epigenetic 
modifiers  
The first study of awakening silent BGCs by the supplementation of epigenetic modifiers was 
the treatment of Aspergillus alternata and Pencillium expansum with the histone deacetylase 
(HDAC) inhibitor  and antifungal drug, trichostatin A (TSA) (Shwab et al., 2007). It 
demonstrated HdaA (histone deacetylase) only regulated genes in the telomere-proximal 
regions, in contrary to LaeA which regulates clusters in both telomere proximal regions and 
the internal regions of the chromosomal arms. (Shwab et al., 2007).  
Since this initial study there have been many supporting reports of the successful awakening 
of BGCs in a diverse array of filamentous fungi (Akone et al., 2016; Asai et al., 2011, 2013, 
2016; Asai, Luo, Obara, Taniguchi, et al., 2012; Asai, Yamamoto, & Oshima, 2012; Asai, 
Yamamoto, Chung, et al., 2012; J. Sun et al., 2012; Williams et al., 2008; Yakasai et al., 2011; 
Yang et al., 2014). There are also some studies applying epigenetic modifiers to marine and 
marine-derived fungi with successful induction of BGCs. The cultivation of the marine-derived 
Figure 8 - Mechanism of deacetylation by sirtuin and nicotinamides 
physiological inhibiting action (Seto & Yoshida, 2014). 
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fungus Penicillium brevicompactum treated with class III HDAC inhibitors nicotinamide and 
sodium butyrate, were found to induce the production of several phenolic compounds. Nine 
new phenolic compounds were isolated from the nicotinamide treatment, three of which 
were found to show antiproliferative activity against HepG2. Two new compounds were also 
isolated from the sodium butyrate treatment (El-Hawary et al., 2018). Two new polyketides 
were isolated from marine fungus Asteromyces cruciatus exposed to SAHA and osmotic stress 
(Igboeli et al., 2019). These studies demonstrate the potential of applying epigenetic modifiers 
to marine and marine-derived fungi. 
1.5 Extraction of secondary metabolites from cultures 
1.5.1 Liquid-liquid extraction using ethyl acetate 
In liquid-liquid extraction (LLE) hydrophobic sample constituents are extracted from aqueous 
samples with a water-immersible organic phase. Volatile organic solvents that are usually used 
include methyl chloride, diethyl ether, pentane, hexane, chloroform and ethyl acetate. Liquid-
liquid extraction works by extracting hydrophobic compounds from the sample to the organic 
phase of the organic solvent. For a successful LLE the extraction efficiency or the recovery 
(extracted amount of compound/original amount of compound) should be close to 100%. The 
extraction efficiency is closely related to the volume of organic solvent and the partition 
coefficient of the analyte of interest. Partition coefficients are defined as the concentration 
ratio of a chemical compound between to immersible solutions at equilibrium (Johanson, 
2010; Pedersen-Bjergaard et al., 2000). 
Extraction efficiency might be increased by increasing the volume of organic solvent relative 
to the sample volume or extracting several times. For extraction of basic or acidic compound, 
pH adjustments to alkaline or acidic range, respectively can ensure high extraction efficiency. 
In addition to analyte enrichment, LLE provides a clean-up of the sample as inorganic salts are 
usually insoluble in the organic solvents used and consequently remain in the sample 
(Pedersen-Bjergaard et al., 2000). 
1.5.2 Solid phase extraction using Diaion® HP-20 
Solid-phase extraction (SPE) using Diaion® HP-20 resin is a more efficient extraction method 
than LLE. It yields quantitative extracts and the process can be automated. By applying this 
technique, many of the disadvantages of liquid-liquid extraction such as incomplete phase 
separation, less than quantitative recoveries and disposal of large quantities of organic 
solvents are avoided (Supelco Analytical, 2004). It is applied as a preconcentration and clean-
up method for analytical samples, purification of chemicals and the extraction of toxic of 
valuable compounds from aqueous samples (J. J. Sun & Fritz, 1992).  
There are a wide range of adsorbents to choose from when performing SPE and the choice of 
solid sorbent is the most crucial factor, which controls the selectivity, affinity, capacity, 
recovery and enrichment (Yavuz et al., 2017). Diaion HP-20 is a non-polar copolymer styrene-
divynibenzene adsorbent resin. It constitutes porous spherical particles of 0.5 mm diameter 
in which compounds in the sample can be attracted into. Diaion HP-20 is considered the most 
effective adsorbent for preconcentration and eliminating toxic compounds in fermentations 
(Sigma-Aldrich, 2020a).  
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1.6 Screening of bioactivity   
The emergence of genomics-based methods in drug discovery has led to an enormous amount 
of analytical data of microbial genomics, transcriptomics and proteomics. To figure out if the 
compounds constituting this data has potential to be utilized as drugs or other agents in a 
biological system, it is essential to identify if they have biological targets. If a compound has 
no biological target it has no drug potential. To study this, bioassays must be performed 
(Malviya & Malviya, 2017; Weller, 2012). The focus was in antibacterial assays that are shortly 
introduced in the following section. 
1.6.1 Antibacterial activity 
The current spread of antimicrobial resistance is one of the greatest global threats to human 
health world-wide causing over 700 000 deaths yearly, and the number is estimated to 
increase to 10 million yearly deaths by 2050 if measures are not put in place. The current rate 
of antibiotic development has not hold up with the rapid development of resistance among 
human pathogenic bacteria. (Genilloud, 2019; Trotter et al., 2019; WHO, 2017) 
The World Health Organization (WHO) have made multi drug resistant pathogens one of their 
top priorities and released a global priority list of antibiotic resistant bacterial to guide 
research and development (table 1). Carbapenem-resistant Pseudomonas aeruginosa and 
carbapenem and 3rd generation cephalosporin resistant Escherichia coli are ranked as some 
of the most critical pathogens on this list. Vancomycin resistant Enterococcus faecalis and 
vancomycin and methicillin resistant Staphylococcus aureus are also of high priority (WHO, 
2017). These four bacteria; E. coli, P. aeruginosa, S. aureus and E. faecalis together with 
Streptococcus agalactiae (not on WHO’s list) were tested against in the screenings for 
antibacterial activity.  
 
Table 1 - The global priority list of antibiotic resistant bacteria presented by WHO (WHO, 2017). 
Priority  Pathogens Resistance 
Critical Acinetobacter baumannii Carbapenem 
Pseudomonas aeruginosa Carbapenem 
Enterobacteriaceae:  
Klebsiella pneumonia, Escherichia coli, 
Enterobacter spp., Serratia spp., Proteus 
spp., Providencia spp., Morganella spp. 
Carbapenem, 
3rd generation cephalosporin 
High Enterococcus faecalis Vancomycin 
Staphylococcus aureus  Methicillin 
Vancomycin  
Helicobacter pylori Clarithromycin  
Campylobacter Fluoroquinolone  
Salmonella spp. Fluoroquinolone  
Neisseria gonorrhoeae 3rd generation cephalosporin 
Fluoroquinolone  
 
Due to the different cultivation approaches applied in this thesis, antibacterial activity had to 
be tested in several different assays. The solid cultures were tested by an agar plug diffusion 
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method, the liquid micro cultures were tested in an agar disc-diffusion method and the 
extracts were tested by a broth dilution method. 
1.6.1.1 Agar plug diffusion method 
In the agar plug diffusion method the microbial strains of interest are first cultivated on agar 
medium. During this growth it is assumed the microbe secretes molecules in the agar medium. 
After cultivation plugs of the microbes are cut out using sterile cork borer and placed either 
with aerial side down on agar inoculated with the microbe tested against, or with the aerial 
side up an empty petri dish which then is filled with liquid agar inoculated with the microbe 
tested against. I will apply the latter method. The activity of the microbial strain tested can be 
evaluated by the size of the inhibition zone around the plug. (Balouiri et al., 2016) 
1.6.1.2 Agar disc-diffusion method 
The agar disk disc-diffusion method is an official method for routine antimicrobial 
susceptibility testing in many clinical laboratories. In this procedure the surfaces of agar plates 
are inoculated by spreading a volume of a standardized inoculum of the test microbe. Filter 
paper discs with samples for testing are evenly dispersed on the solidified surfaces (Balouiri 
et al., 2016; Hudzicki, 2009). The bacteria tested against can be classified as susceptible, 
intermediate or resistant to the extracts based on the size of the inhibition zone or the lack of 
one. This method is not able to distinguish between bactericidal and bacteriostatic effects as 
inhibition of bacterial growth does not necessarily mean bacterial death. However, the 
advantages of this assay include simple design, low cost, and ability to test a high number of 
microbes and antimicrobial agents. The minimum inhibitory concentration (MIC) cannot be 
determined by dilution methods as it is not possible to quantify the amount of compounds 
diffused into the agar (Balouiri et al., 2016).  
1.6.1.3 Broth dilution method 
Broth dilution testing is commonly performed in 96-well microtitration plate format. 
Generally, each well is added the microbial agents for testing diluted in a culture medium. 
Then each well the microbial strain tested against, inoculated in the same medium to a 
standardized concentration, mixed and incubated. The activity of the microbial agents tested 
can be determined by measuring the optical density (OD), the amount of light absorbed by 
the samples, in relation to a blank sample only containing assay medium. Dense microbial 
growth will give a high OD value and indicate poor antimicrobial inhibition, while a low OD 
value indicates no or sparse microbial growth and successful microbial inhibition (Balouiri et 
al., 2016).  
The MIC value recorded is the lowest concentration of the tested agent able to inhibit 
visible/detectable growth of the microbe screened against. it is usually expressed as μg/mL or 
mg/L. Dilution methods are the most suitable for determination of MIC values as they can 
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1.6.2 Antibiofilm activity 
In the antibiofilm assay the samples ability to inhibit the formation of biofilm by 
Staphylococcus epidermidis is investigated, with non-biofilm forming bacterium 
Staphylococcus haemolyticus as planktonic growth control. In the assay, S. epidermidis biofilm 
is grown on the surface of polystyrene wells of 96-well plates filled with liquid media. Extracts 
are then added to test their ability to inhibit biofilm formation. After incubation the biomass 
build-up is quantified by crystal violet staining. After staining the crystal violet is removed and 
washed and dried before the biomass is dissolved in ethanol. The extracts are then evaluated 
on their inhibition of biofilm formation by their optical density as wells with biofilm will be 
stronger colored than wells without or small amounts of biofilm (Kragh et al., 2019; O’Toole 
et al., 1999).  
S. epidermidis is a Gram-positive bacterium of the Staphylococcaceae family. It is a commensal 
bacterium of the microbiota and inhabits multiple skin surfaces. S. epidermis is one of the 
most frequent causes of medical device-related infections resulting from its biofilm-forming 
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2 Background 
 
Marbio is a high-throughput analytical laboratory with a broad range of chromatographic and 
spectrometric tools for extracting and fractionating biological samples and biochemical and 
cellular assays for screening of samples for bioactivity (Svenson, 2013). Collected 
microorganisms are cultivated and applied the OSMAC approach for inducing secondary 
metabolism. However, identifying the exact culture conditions that induces secondary 
metabolite production might be a labor-intensive approach as the biosynthetic gene clusters 
producing secondary metabolites are repressed by many levels of transcription regulation 
(Frisvad, 2012). 
Silent BGCs are physically unavailable for transcription because their DNA are highly 
compressed in heterochromatin and hidden away from transcription enzymes. This is due to 
the epigenetic regulation of the fungal genomes performed by the epigenetic machinery 
(Pfannenstiel & Keller, 2019). In this thesis I will be applying the strategy of inducing the 
activation of biosynthetic gene clusters in marine filamentous fungi by the supplementation 
of small molecule chemical inhibitors as a way of manipulating the epigenetic machinery of 
the fungi to keep the BGCs transcriptionally accessible. This method has been acknowledged 
to be more effective in inducing the activation of silent BGCs than the OSMAC approach and 
is a simpler and less labor intensive than the other strategies previously mentions. As many 
fungi still are recalcitrant to genetic transformation, the supplementation of small molecule 
inhibitors might be more applicable to the many species of filamentous fungi less responsive 
to genetic manipulation (Pfannenstiel & Keller, 2019).  
2.1 Epigenetic modifiers applied to Marbio’s marine fungi 
Epigeneitc modifiers have not previously been applied to the selection of marine filamentous 
fungi studied in this thesis. Consequently, there were no data available on which modifiers are 
effective and not in these strains. It was therefore chosen to implement one inhibitor of each 
of the three major groups: the DNMT inhibitor 5-azacytidine, the HDAC inhibitor suberoyl bis-
hydroxamic acid (SBHA) (also known as suberohydroxamic acid) and the sirtuin inhibitor 
nicotinamide (figure 9). These inhibitors were selected because of the many report of 
successful induction of BGCs by their application, they constituted the best economic 









Although RG-108 is less hazardous (acute toxic if swallowed and acute aquatic toxic) compared 
to 5-azacytidine (acute toxic if swallowed and carcinogenic), 5-azacytidine was selected as the 
DNMT inhibitor. This is because it has the most reported cases of inducing secondary 
Figure 9 - Chemical structure of A) 5-azacytidine, B) SBHA and C) nicotinamide 
B C A 
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metabolism and a significantly lower price than the alternative RG-108 (Appendix 3). SBHA 
was selected as the HDAC inhibitor as it is much safer to apply than SAHA and VPA (both posing 
reproductive toxicity) and substantially cheaper than the widely used SAHA. Lastly 
nicotinamide was the selected sirtuin inhibitor because of the significantly lower price 
compared to the two alternative inhibitors, sirtinol and splitomicin.  
2.2 Selection of fungal strains  
I started the MSc work with eight fungal isolates listed in table 2. These fungal isolates were 
selected for investigation because they were all poorly studied in terms of bioactivity and were 
all already whole genome sequenced or planned to be sequenced. So I had the possibility to 
link metabolites with BGCs.  These were subjected to two liquid and solid cultivation in four 
different growth media: M6, M6 LPS (lipopolysaccharide), FMAP, and FMAP LPS, with agarose 
in the solid media.  
 
Table 2 - Fungal isolates investigated 
Taxon Isolate name  Source of isolation Reference 




018bII1.1 Driftwood (Rämä et al., 
2014) 
Tolypocladium inflatum 010cU1.3 Driftwood (Rämä et al., 
2014) 
Calycina marina TRa3180AII.4 Alga (Baral & Rämä, 
2015) 
Typhula sp. TRa3160C Alga (Rämä & 
Spatafora, 2019b) 
Mytilinidion sp. M16HEL1360D1-10.1 Driftwood (Hagestad et al., 
2019) 
Lulworthia sp. TRa3202.III.1 Fruiting body (on 
driftwood) 
(Hagestad et al., 
2019) 
Acremonium sp. TS7 Deep-sea sponge (Rämä & 
Spatafora, 2019a) 
 
2.3 Metabolic potential of Acremonium sp. (TS7) 
Prior to thesis, TS7 had been genome sequenced and draft genome assembled. Following 
genome annotation and BGC prediction done by Ph.D. student Ole Christian Hagestad using 
antiSMASH revealed 16 NRPS, 9 terpene, 6 PKS, 1 indole, 1 phosphonate, and 3 NRPS-PKS 
hybrid BGCs to a total of 36 BGCs. Homology search of TS7 BGCs revealed clusters likely to 
produce homologous compounds of botrydial, helvolic acid, cephalosporin C, ascochlorin and 
leucinostatin A.   
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3 Workflow 
This thesis was performed at Marbio – an analytical platform for natural products. This was 
the first study into supplying epigenetic modifying compounds to any microbial culture at the 
Marbio research laboratory, and because of the time constraints of conducting a master’s 
thesis not all aspects of optimising the use of epigenetic modifiers as a way of inducing 
biosynthetic gene clusters were studied. Starting out with cultivating the 8 fungal isolates 
Digitatispora marina (008cD1.1), Amylocarpus encephaloides (018bII1.1), Tolypocladium 
inflatum (010cU1.3), Calycina marina (TRa3180AII.4), Typhula sp. (TRa3160C), Mytilinidion sp. 
(M16HEL1360D1-10.1), Lulworthia sp. (TRa3202.III.1), and Acremonium sp. (TS7) in liquid and 
solid media for 30 days and subsequently subjecting the cultures to antibacterial and protease 
activity testing. Based on these preliminary results, the 3 fungal isolates 008cD1.1, TRa3160C, 
and TS7 were selected for further cultivation for 30 days on solid media with epigenetic 
modifiers 5-azacytidine, SBHA, and nicotinamide. After cultivation these cultures were 
screened for antibacterial and antifungal activity. Because of the uniform activity of TS7, and 
lack of activity by 008cD1.1 and TRa3160C, all solid TS7 cultures were combined in one liquid-
liquid extraction and 008cD1.1 and TRa3160C were not further studied. TS7 were subjected 
for a final cultivation in liquid media to investigate if the epigenetic modifiers might work 
better in a liquid environment and extracted by solid phase extraction after 16 days of 
cultivation. All extracts were screened for antibacterial, antibiofilm, antifungal and anticancer 
activity and analyzed by MS (figure 10). 
Figure 10 - Workflow of the thesis. The original selection of isolates was first cultivated in liquid and solid media and 
subsequently tested for bioactivity. Based on these results the three most promising fungi were subjected for new 
rounds of cultivation on solid media with added epigenetic modifiers and thereafter tested for bioactivity and 
analyzed using mass spectrometry. On the basis of these results one fungal isolate was selected for further 
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4 Aim of the Thesis 
 
The main aim of this thesis was to identify if applying epigenetic modifiers would have an 
effect on secondary metabolites produced by the studied marine filamentous fungi. 
Other aims were to: 
¨ Identify bioactive secondary metabolites, and study which epigenetic modifiers 
yielded their production 
¨ Develop a method for implementing the application of epigenetic modifiers as part of 
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5 Materials and methods  
5.1 Initial cultivation of fungi on solid and liquid media 
 
Table 3 - Products and equipment used in the initial cultivation. 
Product/Equipment Product ID/Equipment 
specifications  
Distributor (Country) 
Herasafe biological safety 
cabinet 
Class II Thermo Fisher Scientific 
(Massachusetts, USA) 
Termaks Cooling Incubator  KB8182 Termaks AS, (Norway) 
Petri dishes, 9 cm diameter 391-0605 VWR International 
(Pennsylvania, USA) 
Deep well storage plates, 96-
well, 2,2 mL 
732-4843 VWR International 
(Pennsylvania, USA) 
 
Initial cultivations of the eight fungal isolates (table 2) was first performed to select which 
isolates to go forward with and cultivate with added epigenetic modifiers. In this initial 
cultivation all fungal isolates were cultivated in both liquid and solid M6, M6 LPS, FMAP, and 
FMAP LPS media (Appendix 1).   
Solid cultures were grown in petri dishes containing 20 mL medium and liquid micro-cultures 
were grown in deep well plates (DWPs) in volumes of 1.5 mL. Fungi were inoculated on solid 
cultures by cutting out plugs of mycelia from established plates and transferring three plugs 
with the aerial side down to each agar plate. In liquid cultures, fungi were inoculated by taking 
plugs from established plates with a syringe and inserting the plugs into the media containing 
wells of the DWPs.  
 
Both solid and liquid cultures were incubated at 10°C for 30 days before screening for 
bioactivity. Solid cultures were only tested for antibacterial activity by the agar plug diffusion 
method (described in section 5.2.1) and the liquid cultures were tested for antibacterial 
activity by the agar disc diffusion method, so that the two antibacterial assays could be easily 
compared. In addition, the liquid micro-cultures were tested for protease activity. After 
cultivation the liquid micro-cultures were centrifuged for 30 minutes at 3 300 G and 
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5.1.1 Characterization of fungal strains  
 
Table 4 - Products and equipment used in the characterization of fungal strains. 
Product/Equipment Product ID/Equipment specifications  Distributor (Country) 
DreamTaq Green PCR 
Master Mix (2X) 
K108/82 Thermo Fisher Scientific 
(Massachusetts, USA) 












Gel Red (10,000 x) 41003 BioTium, (California, USA) 
Agarose Ultrapure™ 15510-027 Life Technologies, 
(California, USA) 
10 x TBE 15581-044 Life Technologies, 
(California, USA) 
DNA ladder  10787-018 Life Technologies, 
(California, USA) 
Agarose gel loading dye 
(6x) 
E190-5ml Amresco®, (Ohio, USA) 
A-SAP Kit  Shrimp Alkaline Phosphatase (70700-
201) and Exonuclease 1 
ArcticZymes, (Norway) 
BigDye 3.1  MH sequencing lab at UiT, 
Norway 
5x sequencing buffer  MH sequencing lab at UiT, 
(Norway) 
Agarose Gel 
electrophorese system  
Owl separation system, B2 model Thermo Fisher Scientific 
(Massachusetts, USA) 
Gel image system GeneFlash  SYNGENE Bio imaging, (UK) 
PCR machine   
Ultra Pure water  L0015 Biochrom Gmbh, (Germany) 
 
To verify the identity of the cultivated fungi and check for contamination of other microbes, 
the internal transcribed spacer (ITS) was sequenced This spacer DNA located between the 
small and large ribosomal subunit rRNA genes, which is used as DNA barcoding of fungal 
species (Fajarningsih, 2016; Lafontaine & Tollervey, 2001). 
DNA samples of fungal mycelia were taken from established solid fungal cultures with an 
inoculation loop and inoculated in 100 μL Ultra Pure water in Eppendorf tubes. The samples 
were vortexed, spun down on table centrifuge and incubated for 30 minutes at -80°C to lyse 
the cells and release their DNA into the water. The amplification PCR (polymerase chain 
reaction) reaction mix was prepared for each fungal sample by mixing the following: 1 μL 
fungal template, 12.5 μL2x Dream Taq, 1 μL (10 μM) forward primer, 1 μL (10 μM) reverse 
primer, and 9.5 μL Ultra Pure water to a volume of 25 μL for each PCR sample. Fungal isolate 
M16HEL1360D1-10.1 was amplified using forward primer ITS5 and reverse primer LR0Ri. The 
remaining fungal isolates were amplified using the ITS5/ITS4 primer pair. The amplification 
PCR was run as specified in table 5. 
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Table 5 - Cycle scheme for amplification PCR 
Initial Denaturation  95°C 5 min 
Cycle x35 Denature 95°C 30 sec 
Annealing 47°C 30 sec 
Elongation 72°C 1 min 
Final Extension 72°C 10 min 
Hold  4°C ∞ 
 
The PCR products were analysed by gel electrophoresis in 1% agarose gel (1 g agarose in 100 
mL 1x TBE buffer) added 10 μL 10,000x GelRed. Loaded 5 μL of each PCR product and 5 μL 1kb 
ladder to the outer wells and ran the gel for 20 min with 180 V. Exposed the gel with UV light. 
The PCR products were purified using the A-SAP Kit by mixing 5 μL of each sample with 1 μL 
Shrimp Alkaline Phosphatase and 1 μL Exonuclease 1. The mixtures were run by PCR machine 
for 15 min at 37°C and 15 min at 80°C to deactivate the enzymes.  
Lastly the sequencing PCR was performed. Prepared the sequencing PCR mix by mixing the 
following: 1 μL fungal template, 1 μL BigDye 3.1, 2 μL 5x sequencing buffer, 1 μL (1 μM) 
forward or reverse primer (in separate samples), and 5 μL Ultra Pure water to a total volume 
of 10 μL. The sequencing PCR reaction was run as specified in table 6. 
 
Table 6 - Cycle scheme for sequencing PCR 
Initial Denaturation  96°C 5 min 
Cycle x30 Denature 96°C 10 sec 
Annealing 47°C 5 sec 
Elongation 60°C 2 min 
Hold  4°C ∞ 
 
After sequencing PCR, the samples were delivered to the sequencing lab at UiT/UNN for 
Sanger sequencing. The sequencing outputs were analyzed in Geneious R10.2 (2017 version) 
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5.1.2 Antibacterial agar disc diffusion assay 
 
Table 7 - Products and equipment used in the antibacterial agar disc diffusion assay. 
Product/Equipment Product ID/Equipment 
specifications 
Distributor (Country) 
Mueller Hinton broth (MH) 275730 Becton, Dickinson and Company 
(New Jersey, USA) 
Brain heart infusion broth 
(BHI) 
53286 Sigma-Aldrich (Missouri, USA) 
Agarose A1296  
 
Sigma-Aldrich (Missouri, USA) 
Blood agar plates  University hospital of North 
Norway (UNN), (Norway) 
Gentamycin (10 mg/mL) A 2712 Merck KGaA (Germany) 
NaCl S3014 Sigma-Aldrich (Missouri, USA) 
MilliQ H2O MilliQ Gradient A10 Merck Millipore KGaA, 
Germany  
Whatman® Antibiotic Assay 
Discs  
WHA2017006 Sigma-Aldrich (Missouri, USA) 
Heated Incubator MIR-262  Panasonic Healthcare (Japan) 
Incubator Unimax 1010  Heidolph Instruments GmbH & 
Co (Germany) 
Herasafe biological safety 
cabinet 
Class II Thermo Fisher Scientific 
(Massachusetts, USA) 
Staphylococcus aureus ATCC® 25923 LGC Standards (UK) 
Escherichia coli ATCC® 25922 LGC Standards (UK) 
Enterococcus faecalis  ATCC® 29212 LGC Standards (UK) 
Pseudomonas aeruginosa ATCC® 27853 LGC Standards (UK) 
Streptococcus agalactiae ATCC® 12386 LGC Standards (UK) 
 
Blood plates of E. coli, P. aeruginoa, S. aureus, E. faecalis and S. agalactiae were prepared and 
incubated at 37°C over-night. A scoop from each bacterial blood plate were inoculated in 2 
mL sterile saline (0.9% NaCl) and vortexed to create a smooth suspension. Plated out 50 μL E. 
coli, P. aeruginoa and S. aureus suspension on MH agar plates and 50 μL E. faecalis and S. 
agalactiae suspension on BHI agar plates. Distributed 5 disc  evenly on each plate. Each disc 
was added 5 μL supernatant to each disc and 5 μL gentamycin (10 mg/mL) as negative control. 
The plates were incubated at 37°C for 24 hours before reading. The activity was measured by 
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5.1.3 Protease activity assay 
 
Table 8 - Products and equipment used in the protease activity assay. 
Product/Equipment Product ID/Equipment 
specifications  
Distributor (Country) 
Tris-HCl T5941 Sigma-Aldrich (Missouri, USA) 
HEPES H4034 Sigma-Aldrich (Missouri, USA) 
NaCl S3014 Sigma-Aldrich (Missouri, USA) 
Suc-Ala-Ala-Pro-Phe-pNA S7388 Sigma-Aldrich (Missouri, USA) 
Protease (reference sample)  ArcticZymes, (Norway) 
CaCl2 72340 Sigma-Aldrich (Missouri, USA) 
96 MicroWell™ plates, 
Nuclon™Δ  
734-2073 VWR International AS, 
Pennsylvania, USA 
MilliQ H2O MilliQ Gradient A10 Merck Millipore KGaA, Germany  
 
90 μL assay mix (3 mL 1M Tris-HCl pH 8.0 at 25°C, 3 mL 0.1 M CaCl2, 0.3 mL 100 mM substrate 
stock and 23.7 mL MilliQ H2O) was transferred to all wells of the micro titer plates and 10 μL 
enzyme dilution buffer (25 mM HEPES, pH 8 and 0.3 M NaCl) to well C-H 11-12 and 10 μL 
reference sample (1.2 U/mL) to well A and B 11-12 (final concentration 0.120 U/mL). 10 μL of 
the supernatants were added in parallels to the remaining wells and read the plates 
immediately. The maximum slope was of the enzyme reactions were calculated, and samples 
with maximum slope above 0.0005 were classified as active. 
5.2 Cultivation of fungi on solid media with epigenetic modifiers 
 
Table 9 - Products and equipment used in the cultivation of fungi on solid media. 
Product/Equipment Product ID/Equipment 
specifications  
Distributor (Country) 
Herasafe biological safety 
cabinet 
Class II Thermo Fisher Scientific 
(Massachusetts, USA) 
Termaks Cooling Incubator  KB8182 Termaks AS, (Norway) 
Petri dishes, 9 cm diameter 391-0605 VWR International (Pennsylvania, USA) 
5-azacytidine 10003160 Fisher Scientific, (Norway) 
SBHA 390585 Sigma-Aldrich (Missouri, USA) 
Nicotinamide 72340 Sigma-Aldrich (Missouri, USA) 
 
Based on preliminary bioassay results, Digitatispora marina (008cD1.1), Typhula sp. 
(TRa3180AII.4) and Acremonium sp. (TS7) were selected for further investigation and 
cultivation with the epigenetic modifiers SBHA, 5-azacytidine, and nicotinamide. 008cD1.1 
and TS7 were cultivated on M6 agar and M6 LPS agar, and Tra3180AII.4 was cultivated on 
Ascophyllum nodosum agar and corn meal agar (Appendix 1). Epigenetic modifiers were added 
to lukewarm solid medium before 20 mL were pipetted in each petri dish. SBHA, 5-azacytidine, 
and nicotinamide were added to concentrations of 500 μM, 50 μM and 50 μM, respectively in 
seven combinations. Plugs from established plates were inoculated on the solidified medium, 
placed with the aerial side against the agar. Three plugs on each plate. Plates were incubated 
at 10°C for 30 days. The cultures established and the combinations of epigenetic modifiers are 
listed in table 10. All combinations were prepared in triplets making a total of 144 plates.  
 
   25 
Table 10 - List of fungal solid cultures with epigenetic modifiers. 5-aza: 5-azacytidine, Nico: nicotinamide, null: no 
epigenetic modifiers added, S: SBHA, A: 5-azacytidine, N: nicotinamide, ANA: Ascophyllum nodosum agar, CMA: 
corn meal agar. 
Fungal strain Culture name  5-aza (μM) SBHA (μM) Nico (μM) 
Acremonium sp. TS7 M6 null  - - - 
Acremonium sp. TS7 M6 S  - 500 - 
Acremonium sp. TS7 M6 A  50 - - 
Acremonium sp. TS7 M6 N   - - 50 
Acremonium sp. TS7 M6 SN  - 500 50 
Acremonium sp. TS7 M6 AS  50 500 - 
Acremonium sp. TS7 M6 AN  50 - 50 
Acremonium sp. TS7 M6 ASN  50 500 50 
Acremonium sp. TS7 M6 LPS null  - - - 
Acremonium sp. TS7 M6 LPS S  - 500 - 
Acremonium sp. TS7 M6 LPS A  50 - - 
Acremonium sp. TS7 M6 LPS N   - - 50 
Acremonium sp. TS7 M6 LPS SN  - 500 50 
Acremonium sp. TS7 M6 LPS AS  50 500 - 
Acremonium sp. TS7 M6 LPS AN  50 - 50 
Acremonium sp. TS7 M6 LPS ASN  50 500 50 
Digitatispora marina 008 M6 null  - - - 
Digitatispora marina 008 M6 S  - 500 - 
Digitatispora marina 008 M6 A  50 - - 
Digitatispora marina 008 M6 N   - - 50 
Digitatispora marina 008 M6 SN  - 500 50 
Digitatispora marina 008 M6 AS  50 500 - 
Digitatispora marina 008 M6 AN  50 - 50 
Digitatispora marina 008 M6 ASN  50 500 50 
Digitatispora marina 008 M6 LPS null  - - - 
Digitatispora marina 008 M6 LPS S  - 500 - 
Digitatispora marina 008 M6 LPS A  50 - - 
Digitatispora marina 008 M6 LPS N   - - 50 
Digitatispora marina 008 M6 LPS SN  - 500 50 
Digitatispora marina 008 M6 LPS AS  50 500 - 
Digitatispora marina 008 M6 LPS AN  50 - 50 
Digitatispora marina 008 M6 LPS ASN  50 500 50 
Typhula sp. 3160 ANA null  - - - 
Typhula sp. 3160 ANA S  - 500 - 
Typhula sp. 3160 ANA A  50 - - 
Typhula sp. 3160 ANA N  - - 50 
Typhula sp. 3160 ANA SN  - 500 50 
Typhula sp. 3160 ANA AS  50 500 - 
Typhula sp. 3160 ANA AN  50 - 50 
Typhula sp. 3160 ANA ASN  50 500 50 
Typhula sp. 3160 CMA null  - - - 
Typhula sp. 3160 CMA S  - 500 - 
Typhula sp. 3160 CMA A  50 - - 
Typhula sp. 3160 CMA N   - - 50 
Typhula sp. 3160 CMA SN  - 500 50 
Typhula sp. 3160 CMA AS  50 500 - 
Typhula sp. 3160 CMA AN  50 - 50 
Typhula sp. 3160 CMA ASN  50 500 50 
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5.2.1 Antibacterial agar plug diffusion assay 
 
Table 11 - Products and equipment used in the antibacterial plug assay. 
Product/Equipment Product ID/Equipment 
specifications 
Distributor (Country) 
Mueller Hinton broth (MH) 275730 Becton, Dickinson and 
Company (New Jersey, USA) 
Brain heart infusion broth 
(BHI) 
53286 Sigma-Aldrich (Missouri, USA) 
Blood agar plates  University hospital of North 
Norway (UNN), (Norway) 
Gentamycin (10 mg/mL) A 2712 Merck KGaA (Germany) 
MilliQ H2O MilliQ Gradient A10 Merck Millipore KGaA, 
Germany  
Heated Incubator MIR-262  Panasonic Healthcare (Japan) 
Incubator Unimax 1010  Heidolph Instruments GmbH & 
Co (Germany) 
Herasafe biological safety 
cabinet 
Class II Thermo Fisher Scientific 
(Massachusetts, USA) 
Staphylococcus aureus ATCC® 25923 LGC Standards (UK) 
Escherichia coli ATCC® 25922 LGC Standards (UK) 
Enterococcus faecalis  ATCC® 29212 LGC Standards (UK) 
Pseudomonas aeruginosa ATCC® 27853 LGC Standards (UK) 
Streptococcus agalactiae ATCC® 12386 LGC Standards (UK) 
 
Solid fungal cultures were tested for antibacterial activity in parallels directly by incubating 
plugs of full-grown fungal cultures in solid medium containing bacteria to study the fungi for 
bacterial growth inhibiting abilities. 
The fungi were screened against the five pathogenic bacteria Staphylococcus aureus, 
Escherichia coli, Enterococcus faecalis, Pseudomonas aeruginosa and Streptococcus 
agalactiae. These were plated out from freeze stock on blood agar plates. The plates were 
incubated over night at 37°C and thereafter stored at 4°C. Overnight cultures of the bacteria 
were prepared by inoculating a scoop of each bacteria from blood plates in 5 mL growth media 
and incubated over night at 37°C with shaking. 
Plugs with mycelia were cut out of fungal plates using a cork borer with diameter of 6 mm and 
placed in empty petri dishes with the aerial side up. 5-6 plugs were placed in each dish, evenly 
dispersed. Inoculated 100 μL overnight cultures of bacteria in 100 mL lukewarm MH (S. aureus, 
E. coli and P. aeruginosa) or BHI (E. faecalis and S. agalactiae) medium with 0.8% agarose. 20 
mL bacterial cultures were then added the petri dishes containing fungal plugs without 
covering the top of the plugs. After the agar had solidified the plates were incubated for 24 
hours at 37°C. After 24 hours the inhibition of bacterial growth was determined by measuring 
the diameter of the inhibition zones around the plugs.  
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5.2.2 Antifungal agar plug diffusion assay 
Candida albicans it is one of the most prevalent fungi of the human microbiota and the 
predominating infection causing fungus. It can act as both a commensal and opportunistic 
pathogen and hold the ability to cause both superficial mucosal and dermal infections as well 
as life-threatening often fatal, bloodstream infections (Calderone & Fonzi, 2001).  
The screening for antifungal activity, was performed in multiple formats like the antibacterial 
screening. The solid cultures were tested for antifungal activity by the agar plug diffusion 
method, while the extracts were tested by the broth dilution method. In both assays the 
activity were tested against Candida albicans with the antifungal agent Amphotericin B as 
negative control. 
Table 12 - Products and equipment used in the antifungal plug assay. 
Product/Equipment Product ID/Equipment 
specifications 
Distributor (Country) 
Potato dextrose agar 70139 Sigma-Aldrich (Missouri, USA) 
RPMI R7755 Sigma-Aldrich (Missouri, USA) 
MOPS M3183 Sigma-Aldrich (Missouri, USA) 
L-glutamine K0302 VWR International 
(Pennsylvania, USA) 
NaCl S5886 Sigma-Aldrich (Missouri, USA) 
Amphotericin B (AMP-B) A 2942 Sigma-Aldrich (Missouri, USA) 
MilliQ H2O MilliQ Gradient A10 Merck Millipore KGaA, 
Germany  
Remel 0.5 McFarland 
Equivalence Turbidity 
Standard  
10026732 Thermo Fisher Scientific 
(Massachusetts, USA) 
Heated Incubator MIR-262  Panasonic Healthcare (Japan) 
Herasafe biological safety 
cabinet 
Class II Thermo Fisher Scientific 
(Massachusetts, USA) 
Candida albicans ATCC® 90028 LGC Standards (UK) 
 
There was no established protocol for testing of solid cultures activity against Candida albicans 
at Marbio, so modifications were made to the established protocol for the testing of liquid 
cultures’ against Candida albicans at Marbio, so modifactions were made to the established 
protocol for testing of liquid cultures against Candida albicans and three alternative methods 
were tested out. 
A scoop of Candida albicans cells from the freeze stock were plated out on potato dextrose 
agar (PDA) and incubated over night at 37°C. 5-8 colonies from the overnight plate were 
resuspended in 5 mL sterile 0.9% NaCl. The suspensions were vortexed for 15 seconds and 
adjusted the cell density to the McFarland standard (1-5 x 106 cells/mL).  
Alternative method 1 - Candida albicans and fungal plugs in the agar 
Plugs were cut out using cork borer of the fully grown fungal solid cultures and placed in empty 
petri dishes with the aerial side up. 100 μL Candida albicans suspension adjusted to the 
McFarland standard, were inoculated and in 100 mL lukewarm PDA. 20 mL Candida albicans 
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inoculated in PDA were added the petri dishes containing the fungal plugs without coving the 
top of the plugs.  
Alternative method 2 - Candida albicans and fungal plugs on top of the agar 
20 μL Candida albicans suspension adjusted to the McFarland standard, were plated out on 
PDA plates. Plugs of the fully grown fungal solid cultures were placed on top with the aerial 
side against the agar. 
Alternative method 3 - Candida albicans inside and fungal plug on top of the 
agar 
100 μL Candida albicans suspension adjusted to the McFarland standard were inoculated in 
100 mL lukewarm PDA. Further, 20 mL suspension were pipetted to empty petri dishes. Plugs 
of the fully grown fungal solid cultures were placed on top with the aerial side against the 
agar. All plates were incubated at 37°C for 48 hours and were examined after 24 and 48 hours. 
 
5.2.3 Ethyl acetate extraction of solid cultures 
 
Table 13 - Products and equipment used in the extraction of fungal solid cultures. 
Product/Equipment Product ID/Equipment 
specifications 
Distributor (Country) 
Ethyl acetate 33211N Sigma-Aldrich (Missouri, USA) 
Whatman® qualitative filter 
paper, grade 3  
1003-090 Sigma-Aldrich (Missouri, USA) 
Rotary Evaporator 
(Rotavapor) 
Laborota Heidolph Instruments GmbH & 
Co. (Germany) 
Heidolph Unimax 1010  Heidolph Instruments GmbH & 
Co (Germany) 
Herasafe biological safety 
cabinet 
Class II Thermo Fisher Scientific 
(Massachusetts, USA) 
 
One of the three triplicate plates of each fungal solid culture with epigenetic modifiers was 
used for bioactivity testing. The two remaining plates for each culture condition were used for 
metabolite extraction. Based on the results from the bioactivity screening it was decided to 
combine all remaining plates of TS7 for one extraction. 32 plates of 20 mL each were 
combined, making a total of 640 mL solid cultures. The cultures were cut into pieces of 
approximately 3mm x 3mm using sterile plastic knife and transferred to 1 L glass Erlenmeyer 
flasks.  
A 1:2 extraction of the solid cultures in the extraction solvent (ethyl acetate) was performed. 
The cultures were extracted three times while shaking under fume hood, first time for 12 
hours and second and third for 3 hours each. The solvent extract was then filtrated through 
Whatman® filter into vacuum flask in fume hood after terminated extraction. Lastly, the 
extract was dried under reduced pressure using rotary evaporator.  
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Before the combined extraction of all solid cultures of TS7, plugs of the cultures were analyzed 
by MS separately. Three plugs of 7 mm were cut out of each full-grown solid culture using a 
1000 μL pipette tip. The plugs were transferred to Eppendorf tubes and inoculated in 1 mL 
extraction solvent (isopropanol:ethyl acetate 1:3) with 1 % formic acid and sonicated for one 
hour. The samples derived from the same plates were combined and evaporated to dryness. 
The dry samples were re-dissolved in 100 μL MeOH, spun down and transferred to MS vials 
for analysis. 
 
5.3 Cultivation of fungi in liquid media  
 
Table 14 - Products and equipment used in the cultivation of fungi in liquid media. 
Product/Equipment Product ID/Equipment 
specifications 
Distributor (Country) 
Herasafe biological safety 
cabinet 
Class II Thermo Fisher Scientific 
(Massachusetts, USA) 
5-azacytidine 10003160 Fisher Scientific, (Norway) 
SBHA 390585 Sigma-Aldrich (Missouri, USA) 
Nicotinamide 72340 Sigma-Aldrich (Missouri, USA) 
 
It is well known that cultivation parameters greatly affects the metabolome of the cultured 
microbes (Bode et al., 2002; VanderMolen et al., 2013), epigenetic modifiers were also 
supplemented to liquid fungal cultures to study if their effects on the liquid cultures compared 
to the solid cultures. It appears that most successful studies of usage of epigenetic modifiers 
to induce fungal secondary metabolism have been cultivating fungi in liquid cultures (Akone 
et al., 2016; Asai et al., 2011; Asai, Yamamoto, & Oshima, 2012; Asai, Luo, Obara, Taniguchi, 
et al., 2012; Asai, Morita, Shirata, Taniguchi, et al., 2012; Asai et al., 2013; El-Hawary et al., 
2018; Igboeli et al., 2019; J. Sun et al., 2012; Yakasai et al., 2011; Yang et al., 2014).  The 
epigenetic modifiers were therefore also applied to liquid cultures. 
As antibacterial activity was recorded from TS7 grown on solid M6, M6 LPS and FMAP LPS 
media in the preliminary antibacterial plug assay with all eight fungal isolates, these media 
were used for the liquid culturing as well. In addition, TS7 were cultivated in ASME medium, 
to have a simpler medium to compare the more complex M6 and FMAP media to. The number 
of combinations of epigenetic modifiers were reduced from 7 in the solid cultivation to 5 in 
the liquid cultivation. The liquid cultures are listed in table 15. 
 
The liquid cultivation was performed based on the experimental procedure of culturing fungi 
with epigenetic modifiers (Asai, Chung, Sakurai, Ozeki, et al., 2012; Asai et al., 2016; El-Hawary 
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Table 15 - List of liquid fungal cultures with added epigenetic modifiers. 
Fungal strain Culture name  5-aza (μM) SBHA (μM) Nico (μM) 
Acremonium sp. TS7 M6 null  - - - 
Acremonium sp. TS7 M6 S  - 500 - 
Acremonium sp. TS7 M6 SN  - 500 50 
Acremonium sp. TS7 M6 AS  50 500 - 
Acremonium sp. TS7 M6 AN  50 - 50 
Acremonium sp. TS7 M6 ASN  50 500 50 
Acremonium sp. TS7 M6 LPS null  - - - 
Acremonium sp. TS7 M6 LPS S  - 500 - 
Acremonium sp. TS7 M6 LPS SN  - 500 50 
Acremonium sp. TS7 M6 LPS AS  50 500 - 
Acremonium sp. TS7 M6 LPS AN  50 - 50 
Acremonium sp. TS7 M6 LPS ASN  50 500 50 
Acremonium sp. TS7 FMAP null  - - - 
Acremonium sp. TS7 FMAP S  - 500 - 
Acremonium sp. TS7 FMAP SN  - 500 50 
Acremonium sp. TS7 FMAP AS  50 500 - 
Acremonium sp. TS7 FMAP AN  50 - 50 
Acremonium sp. TS7 FMAP ASN  50 500 50 
Acremonium sp. TS7 FMAP LPS null  - - - 
Acremonium sp. TS7 FMAP LPS S  - 500 - 
Acremonium sp. TS7 FMAP LPS SN  - 500 50 
Acremonium sp. TS7 FMAP LPS AS  50 500 - 
Acremonium sp. TS7 FMAP LPS AN  50 - 50 
Acremonium sp. TS7 FMAP LPS ASN  50 500 50 
Acremonium sp. TS7 ASME null  - - - 
Acremonium sp. TS7 ASME S  - 500 - 
Acremonium sp. TS7 ASME SN  - 500 50 
Acremonium sp. TS7 ASME AS  50 500 - 
Acremonium sp. TS7 ASME AN  50 - 50 
Acremonium sp. TS7 ASME ASN  50 500 50 
 
Full-grown agar plates with TS7 were cut into pieces of approximately 3 mm x 3 mm using 
sterile plastic knife. One fourth of each plate were transferred into sterile 100 mL Erlenmeyer 
flasks and inoculated in 75 mL M6 medium to prepare seed cultures. These were incubated at 
13°C with shaking at 200 rpm for 3 days, when sufficient growth was observed. 25 mL seed 
cultures were inoculated in 250 mL medium in 1 L Erlenmeyer flasks and incubated static for 
16 days at 13°C. Epigenetic modifiers, 5-azacytidine, SBHA and nicotinamide were added after 
9 days of incubation at volumes of 50 μL, 500 μL and 50 μL, respectively. Cultures were placed 
on shaker for 4 hours after addition of epigenetic modifiers to evenly distribute the modifiers 
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5.3.1 Extraction of liquid fungal culture 
 
Table 16 - Products and equipment used in the extraction of the liquid fungal cultures. 
Product/Equipment Product ID/Equipment 
specifications 
Distributor (Country) 
Methanol 34860 Sigma-Aldrich (Missouri, USA) 
Diaion® HP-20 13607 Sigma-Aldrich (Missouri, USA) 
MilliQ H2O MilliQ Gradient A10 Merck Millipore KGaA, 
Germany  
Cheesecloth filter, fine mesh  Dansk Hjemmeproduksjon 
(Denmark) 
Whatman® qualitative filter 
paper, grade 3 
1003-090 Sigma-Aldrich (Missouri, USA) 
Rotary Evaporator 
(Rotavapor) 
Laborota Heidolph Instruments GmbH & 
Co. (Germany) 
 
The liquid fungal cultures were extracted using resin Diaion HP-20 with affinity for non-polar 
compounds.  
Resin was added to the cultures 3 days before extraction at 40 g/L culture. To activate the 
resin, 75 mL MeOH was added to the 10 grams of resin for each 250 mL fungal culture in 100 
mL Erlenmeyer flasks. The flasks were shaken to make sure all resin beads were in contact 
with the MeOH and left for 1 hour. All MeOH was carefully removed and replaced with 75 mL 
MilliQ H2O, shaken briefly to make sure all resin beads were in contact with the MilliQ H2O 
and left for 30 minutes. MilliQ H2O was removed from the resin, before the resin was added 
to the culture flasks. After addition of resin the incubation was continued with shaking at 100 
rpm at 13°C.   
The cultures were filtrated through a cheesecloth using vacuum. To make the hydrophobic 
cheesecloth stick to the funnel it was first moistened with MeOH and washed with MilliQ H2O 
to remove traces of MeOH. The cultures were then carefully filtered to remove the growth 
media. The culture flasks were rinsed with MilliQ H2O and transferred the cheesecloth and 
resin back into the now empty culture flasks. 200 mL MeOH was added and extracted for 1 
hour while shaking.  
The second filtration was through a Whatman no. 3 filter. The filter was moisten with MeOH 
to make it stick to the funnel and the extract carefully filtrated with vacuum, making sure the 
resin stayed in the culture flasks. Added 200 mL MeOH to the culture flasks and extracted 
once more for 30 minutes. Filtrated again through the Whatman no. 3 filter. The filtrates were 
collected and transferred to round flasks before drying under reduced pressure using 
rotavapor. The extraction of each liquid fungal culture was performed separately. 
Based on the number of extracts it was decided to skip the time-consuming fractionation step 
and test the crude extracts directly in bioassays. To prepare the extracts for bioassay testing 
they were, after drying, weighted and dissolved in MeOH to 40 mg/mL. 1 mL were then 
transferred to deep well plate and freeze dried. The freeze-dried extracts were then dissolved 
in 2.5% DMSO and MilliQ H2O to stock solution of 1 mg/mL.  
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5.3.2 Antifungal broth dilution assay 
 
Table 17 - Products and equipment used in the antifungal broth dilution assay. 
Product/Equipment Product ID/Equipment 
specifications 
Distributor (Country) 
Potato dextrose agar 70139 Sigma-Aldrich (Missouri, USA) 
RPMI  R7755 Sigma-Aldrich (Missouri, USA) 
MOPS M3183 Sigma-Aldrich (Missouri, USA) 
L-glutamine K0302 VWR International 
(Pennsylvania, USA) 
NaCl S5886 Sigma-Aldrich (Missouri, USA) 
Amphotericin B (AMP-B) A2942 Sigma-Aldrich (Missouri, USA) 
MilliQ H2O MilliQ Gradient A10 Merck Millipore KGaA, 
Germany  
Remel 0.5 McFarland 
Equivalence Turbidity 
Standard 
10026723 Thermo Fisher Scientific 
(Massachusetts, USA) 
96 MicroWell™, Nunclon™∆, U 
bottom 
734-1192 VWR International 
(Pennsylvania, USA) 
Sanyo Incubator MIP-262 
 
 Sanyo Electric Biochemical 
(Japan) 
Heidolph Unimax 1010  Heidolph Instruments GmbH & 
Co (Germany) 
Victor Multilabel Counter 1420 Multilabel Counter Perkin Elmer (Massachusetts, 
USA) 
Herasafe biological safety 
cabinet 
Class II Thermo Fisher Scientific 
(Massachusetts, USA) 
Candida albicans ATCC® 90028  
 
Candida albicans was collected from freeze stock and plated out on PDA plate. The plate was 
incubated over night at 37°C. 5-8 colonies from the overnight plate were inoculated in 5 mL 
sterile 0.9% NaCl. Corrected the cell density to 1-5 x 106 cells/mL in 0.9% NaCl using the 0.5 
McFarland standard as guide. The Candida suspension were then diluted 1:50 in 0.9% NaCl 
and thereafter 1:20 in assay medium (10.4 g RPMI, 34.53 g MOPS, 1 L MilliQ H2O, and 10.25 g 
L-glutamine (added after autoclavation)) 
The assay was performed in 96 MicroWell™ plates with rounded wells. Stock solutions of the 
extracts (1 mg/ml) were diluted to 500 μg/mL in assay medium and 100 μg/mL were added in 
two parallels as illustrated in figure 11.  Further 100 μL diluted Candida suspension were then 
added to the same wells to a total of 200 μL in each well. As antifungal control, 100 μL 16 
μg/mL Amphotericin B (AMP-B) diluted in sterile MilliQ H2O + 100 μL diluted Candida 
suspension was added to wells B10-G10. As growth control 100 μL sterile MilliQ H2O + 100 μL 
diluted Candida suspension were added wells B11-G11. As medium control 100 μL assay 
medium + 100 μL sterile MilliQ H2O were added wells B12-G12. Because of evaporation all 
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 1 2 3 4 5 6 7 8 9 10 11 12 
A             
B  1 2 3 4 5 6 7 8 A G M 
C  1 2 3 4 5 6 7 8 A G M 
D  9 10 11 12 13 14 15 16 A G M 
E  9 10 11 12 13 14 15 16 A G M 
F  17 18 19 20 21 22 23 24 A G M 
G  17 18 19 20 21 22 23 24 A G M 
H             
Figure 11 - Plate set up for Candida assay. Extracts were added to blue colored wells in parallels as illustrated. 
Ampotericin B controls were added wells marked “A”, growth controls were added wells marked “G”, and media 
controls were added wells marked “M”. 
Optical density (OD) at 600 nm was measured directly after addition of Candida suspension 
before incubation start. OD was measured again after 24 and 48 hours of incubation at 37°C. 
 
5.3.3 Antibacterial broth dilution assay 
 
Table 18 - Products and equipment for the antibacterial broth dilution assay. 
Product/Equipment Product ID/Equipment 
specifications 
Distributor (Country) 
Mueller Hinton broth (MH) 275730 Becton, Dickinson and 
Company (New Jersey, USA) 
Brain heart infusion broth 
(BHI) 
53286 Sigma-Aldrich (Missouri, USA) 
Luria-Bertoni plates  University hospital of North 
Norway (UNN), (Norway) 
Blood agar plates  University hospital of North 
Norway (UNN), (Norway) 
96 MicroWell™ plates, 
Nuclon™Δ  
734-2073 VWR International AS, 
Pennsylvania, USA 
Gentamycin (10 mg/mL) A 2712 Merck KGaA (Germany) 
MilliQ H2O MilliQ Gradient A10 Merck Millipore KGaA, 
Germany  
Sanyo Incubator MIP-262 
 
 Sanyo Electric Biochemical 
(Japan) 
Heidolph Unimax 1010  Heidolph Instruments GmbH & 
Co (Germany) 
Victor Multilabel Counter 1420 Multilabel Counter Perkin Elmer (Massachusetts, 
USA) 
Herasafe biological safety 
cabinet 
Class II Thermo Fisher Scientific 
(Massachusetts, USA) 
Staphylococcus aureus ATCC® 25923 LGC Standards (UK) 
Escherichia coli ATCC® 25922 LGC Standards (UK) 
Enterococcus faecalis  ATCC® 29212 LGC Standards (UK) 
Pseudomonas aeruginosa ATCC® 27853 LGC Standards (UK) 
Streptococcus agalactiae ATCC® 12386 LGC Standards (UK) 
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Freeze stock of the bacteria were collected and transferred to blood agar plates. The plates 
were incubated overnight at 37°C and stored at 4°C. Overnight cultures were prepared by 
inoculating a scoop of the bacteria in 8 mL growth medium. 2 mL overnight culture was 
inoculated in 25 mL fresh medium in sterile Erlenmeyer flasks and incubated each bacterium 
as specified in table 19 at 37°C with shaking.  
 
Table 19 – Incubation parameters for bacteria used in MIC assay. 
Bacterial strain Medium Incubation 
time  
Bacterial density 
S. aureus  MH-broth 2.5 hours 0,5-3x105 CFU/mL (2500-15000 CFU/well) 
E. coli  MH-broth 1.5 hours 0,5-3x105  CFU/mL (2500-15000 CFU/well) 
E. faecalis  BHI-broth 1.5 hours 0,5-3x105  CFU/mL (2500-15000 CFU/well) 
P. aeruginosa MH-broth 2.5 hours 0,5-3x104 CFU/mL (2500-15000 CFU/well) 
S. agalactiae BHI-broth 1.5 hours 0,5-3x105  CFU/mL (2500-15000 CFU/well) 
 
After completed incubation, the bacterial cultures were diluted 1:1000 in their appropriate 
growth medium. Stock solutions of extracts were diluted to 100 μg/mL in sterile MilliQ H2O. 
In the primary screening for antibacterial activity all extracts were tested at a final 
concentration of 50 μg/mL. In the secondary screening the extracts were tested at 50, 25, 10, 
and 1 μg/mL, both rounds of screening in duplicates.  
50 μL diluted extracts were added to column 2-11, as illustrated in figure 12, to five microtiter 
plates, one for each bacterial strain. Thereafter 50 μL diluted bacterial suspension was added 
to the same wells. Medium control constituting 50 μL growth medium + 50 μL sterile MilliQ 
H2O were added column 1. And growth control, 50 μL bacterial suspension + 50 μL sterile 
MilliQ H2O were added column 12.  
 
 1 2 3 4 5 6 7 8 9 10 11 12 
A M 1 1 9 9 17 17 25 25 33 33 G 
B M 2 2 10 10 18 18 26 26 34 34 G 
C M 3 3 11 11 19 19 27 27 35 35 G 
D M 4 4 12 12 20 20 28 28 36 36 G 
E M 5 5 13 13 21 21 29 29 37 37 G 
F M 6 6 14 14 22 22 30 30 38 38 G 
G M 7 7 15 15 23 23 31 31 39 39 G 
H M 8 8 16 16 24 24 32 32 40 40 G 
Figure 12 - Plate set up for the antibacterial MIC assay. Extracts were added blue colored wells added numbered 
wells. G: growth control (MilliQ H2O + bacterial suspension), M: medium control (growth medium + MilliQ H2O). 
The plates were incubated overnight at 37°C. Before reading, the plates were inspected for 
observable inhibition and thereafter read using Victor plate reader by measuring the 
absorbance (Abs) at 600 nm. The extracts were then classified as active, questionable or 
inactive by the threshold Abs600 values: 
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Active ≤ 0.05 
Questionable 0.05 – 0.09 
Inactive ≥ 0.09 
 
In the assay design used for MIC screening the antibacterial activity is tested in two rounds. 
The first round all samples are tested at 50 μM and in the subsequent round only the samples 
that exhibited activity are retested in a dilution series to identify the MIC value. However, as 
no actives were observed at 50 μM, the second round of dilution series testing was not 
performed. 
 
5.3.4 Antibiofilm assay 
In the antibiofilm assay the extracts ability to inhibit the formation of biofilm by the biofilm 
producing bacteria Staphylococcus epidermidis was evaluated. The non-biofilm producing 
bacteria Staphylococcus haemolyticus was used as negative control and the extracts were 
tested in triplets. 
Table 20 - Products and equipment used in the biofilm assay. 
Product/Equipment Product ID/Equipment 
specifications 
Distributor (Country) 
Tryptic soy broth (TBS) 1.05459 Merck KgaA (Germany) 
Dextrose (Glucose) D9434 Sigma-Aldrich (Missouri, USA) 
Ethanol 24106 Sigma-Aldrich (Missouri, USA) 
Crystal violet  1.15940 Merck KgaA (Germany) 
MilliQ H2O MilliQ Gradient A10 Merck Millipore KGaA, 
Germany  
Blood agar plates  University hospital of North 
Norway (UNN), (Norway) 
96 MicroWell™ plates, 
Nuclon™Δ  
734-2073 VWR International, 
Pennsylvania, USA 
Sanyo Incubator MIP-262 
 
 Sanyo Electric Biochemical 
(Japan) 
Heidolph Unimax 1010  Heidolph Instruments GmbH & 
Co (Germany) 
Victor Multilabel Counter 1420 Multilabel Counter Perkin Elmer (Massachusetts, 
USA) 
Herasafe biological safety 
cabinet 
Class II Thermo Fisher Scientific 
(Massachusetts, USA) 
Staphylococcus epidermis  ATCC® 35984 LGC Standards (UK) 
Staphylococcus haemolyticus Clinical isolate 8-7 A University hospital of North 
Norway (UNN), (Norway) 
  
Freeze stock of Staphylococcus epidermidis and Staphylococcus haemolyticus was collected 
and transferred to blood agar plates. The plates were incubated overnight at 37°C and stored 
at 4°C. 
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Overnight cultures were prepared by inoculating a scoop of each bacterial strain in 5 mL TBS 
medium and incubated with shaking overnight at 37°C. The overnight cultures were diluted 
1:100 in fresh TBS medium with 1% glucose. The stock solution of the extracts were diluted to 
100 μg/mL in MilliQ H2O. 50 μL of the extracts were transferred to the numbed wells, and 50 
μL MilliQ H2O to the remaining wells as illustrated in figure 13. 50 μL S. epidermidis suspension 
with 1% glucose were transferred to column 1-10, and 50 μL S. haemolyticus suspension with 
1% glucose were transferred to column 11 and 50 μL TBS medium with 1% glucose to column 
12.  
 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 1 1 1 9 9 9 17 17 17 G N M 
B 2 2 2 10 10 10 18 18 18 G N M 
C 3 3 3 11 11 11 19 19 19 G N M 
D 4 4 4 12 12 12 20 20 20 G N M 
E 5 5 5 13 13 13 21 21 21 G N M 
F 6 6 6 14 14 14 22 22 22 G N M 
G 7 7 7 15 15 15 23 23 23 G N M 
H 8 8 8 16 16 16 24 24 24 G N M 
Figure 13 - Plate set up for the biofilm assay. Extracts were added the blue colored wells, dispersed as illustrated 
in triplets. G: growth control (S. epidermidis + MilliQ H2O), N: negative control (S. haemolyticus + MilliQ H2O), and 
M: medium control (TBS medium + MilliQ H2O). 
Incubated the plates over night at 37°C. Examined the plates for lethal effects on the bacteria. 
Removed the bacterial suspensions from all wells by tapping the plates against cell paper. 
Rinsed the plates with water and tapped the plates dry against the cell paper. Fixated the 
biofilm by incubating at 55°C for 1 hour. After fixation, 70 μL 0.1% crystal violet were added 
to the plates for 5 minutes to color the biofilm. The crystal violet was removed by tapping 
against cell paper. Cleansed the plates twice with water and dried at 55°C for 1 hour. Then 70 
μL 70% ethanol were added all wells and incubated for 10 minutes with shaking at room 
temperature. Absorbance at 600 nm were measured using Victor plate reader. The extracts 
were classified as active (A), inactive (I) or questionable (Q) by the threshold Abs600 values: 
 
Active: OD < 30 % of growth control 
Questionable: OD = 30-40% of growth control 
Inactive: OD > 40% of growth control 
 
5.3.5 Anticancer assay 
In the anticancer assay the extracts were investigated for toxic effects on the human cancer 
cell lines A2058 (human melanoma), HepG2 (human hepatocellular carcinoma) and MCF7 
(human breast adenocarcinoma), and the non-cancerous lung fibroblast cell line MRC5 as 
control for normal human cells and toxicity.  
The anticancer activity of the extracts were investigated by performing the CellTiter 96® 
AQueous One Solution Cell Proliferation Assay. This is a colorimetric method that can be applied 
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to find the number of viable cells in proliferation or cytotoxicity assays. the CellTiter 96® 
AQueous One Solution Reagent contains the yellow colored novel tetrazolium compound [3-
(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, 
inner salt; MTS]. This reagent is added to the micro titer plate after incubation 1-4 hours 
before reading of assay results. In living cells, the MTS tetrazolium compound is bioreduced 
to a red colored formazan product that is soluble in the culture medium. Measured at 490nm, 
the amount of formazan is directly proportional to the number of living cells in the culture 
(Promega Corporation, 2012). 
 
Table 21 - Products and equipment used in the cancer assay. 
Product/Equipment Product ID/Equipment 
specifications 
Distributor (Country) 
Earle’s Minimal Essential 
Medium (E-MEM) with 20 mM 
HEPES 
F4315 Merck KGaA (Germany) 
Roswell Park Memorial 
Institute medium (RPMI) 1640 
FG 1383 Merck KGaA (Germany) 
Dulbecco’s Modified Eagle 
Meduim (D-MEM), high 
glucose, GlutaMAX™ 
Supplement, HEPES 
32430027 Thermo Fisher Scientific 
(Massachusetts, USA) 
Non-essential amino acids 
(NEA) (100x) 
K0302 Merck KGaA (Germany) 
L-Alanyl-L-Glutamine (200 
mM) 
K 0302 Merck KGaA (Germany) 
CellTiter 96® Aqueous One 
Solution Reagent 
G358B Promega (Wisconsin, USA) 
Gentamycin (10 mg/mL) A 2712 Merck KGaA (Germany) 
Trypsin (1:250) 27250018 Thermo Fisher Scientific 
(Massachusetts, USA) 
Triton™ X-100 T8787 Sigma-Aldrich (Missouri, USA) 
Trypan blue T 6146 Sigma-Aldrich (Missouri, USA) 
96 MicroWell™ plates, 
Nuclon™Δ  
734-2073 VWR International AS, 
Pennsylvania, USA  
DTX 880 Multimode Detector  Beckman Coulter 
HeraCell Vios 160L CO2 
Incubator, Thermo Scientific 
 Thermo Fisher Scientific 
(Massachusetts, USA) 
Herasafe biological safety 
cabinet 
Class II Thermo Fisher Scientific 
(Massachusetts, USA) 
A2058 ATCC® CRL-11147™ LGC Standards (UK) 
MCF7 ATCC® HTB-22 LGC Standards (UK) 
MRC5 ATCC® CCL-171 LGC Standards (UK) 
HepG2 ATCC® HB-8065 LGC Standards (UK) 
 
RPMI, D-MEM, PBS and Trypsin were preheated to 37°C. Cell culture flasks were collected 
from incubator and media were removed from the cells. 10 mL PBS were transferred to culture 
flasks to wash the cells for 1 minute before removal. Thereafter, 5 mL trypsin were transferred 
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to the culture flasks until the cells detached from the flask wall. The cultures were inspected 
under microscope to conform that the cells had detached from the flask. The cells were 
resuspended in 10 mL growth medium (D-MEM for A2058, E-MEM for HepG2, MCF7 and 
MRC5). 100 μL cell suspension were mixed with 100 μL Trypan Blue in an Eppendorf tube. 10 
μL of the mixture were transferred to Bürker-Türk counting chamber and the cells were 
counted under the microscope. The cell density was adjusted to 2 x 104 cells/mL, before 100 
μL cell suspension were added to each well achieving a final concentration of 2000 cells per 
well for A2058 and MCF7, 4000 for MRC5 and 20 000 cells per well for HepG2. The plates were 
incubated overnight at 37°C, 5% CO2. 
Growth media were removed from all wells and replaced with 5 μL of the extracts in triples 
and 95 μL fresh media in the numbered wells as illustrated in figure 14. Positive control (90 μL 
growth media + 10 μL DMSO) were added wells marked “P”. The remaining wells were added 
100 μL growth media, including the wells marked N (negative control). Incubated the HepG2 
plates for 24 hours and the A2058, MCF7 and MRC5 plates for 72 hours at 37°C, 5% CO2. 
 
 1 2 3 4 5 6 7 8 9 10 11 12 
A             
B  1 2 3 4 5 6 7 8 N   
C  1 2 3 4 5 6 7 8 N   
D  1 2 3 4 5 6 7 8 N   
E  9 10 11 12 13 14 15 16 N   
F  9 10 11 12 13 14 15 16   G 
G  9 10 11 12 13 14 15 16   G 
H            G 
Figure 14 - Plate set up for the cancer assay. Extracts were added blue colored, numbered wells in triplets, P: 
positive control (growth media + DMSO), N: negative control (growth media). All remaining wells were only added 
growth media.  
 
Before reading, 10 μL Aqueous One Solution (AQOS) were added to each well, the plates were 
then incubated for 1 hour at 37°C, 5% CO2. Thereafter the plates were read using DTX 880 
Multimode Detector by measuring the absorbance at 485 nm. The percentage survival of 
cancer cells were calculated, and based on this estimate the extracts were classified as active 
(A), inactive (I) or questionable (Q) according to the threshold values: 
 
Active < 50% survival 
Questionable = 50-60% survival 
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5.4 Mass spectrometry 
 
Mass spectrometry (MS) was used to analyze all the solid cultures with epigenetic modifiers, 
the ethyl acetate extract of the solid cultures as well as the solid phase extracts of the liquid 
cultures with epigenetic modifiers. 
To prepare samples for the MS run, 20 μL of each extract were added 100 μL MS grade MeOH 
to dilute the samples in Eppendorf tubes. All MS samples were then centrifuged for 10 min at 
13 000 rpm to spin down particles that can clog the MS machine. Transferred 100 μL of each 
sample to MS vials. The Waters Acquity I-class UPLC system interfaced with a PDA Detector 
and VION IMS-qTOF was used for the UPLC-HR-MS analysis. Electrospray ionization (ESI) in 
positive mode and detected wavelengths of 190-500nm was applied. The following VION IMS 
qTOF settings were applied for the UPLC-HR_MS analysis: 0.80 kV capillary voltage, 50 l/h cone 
gas, desolvation temperature of 350°C, 800 L/h desolvation gas, source temperature of 120°C, 
acquisition range of 50-2000 m/z. The system was controlled by UNIFY 1.8.2 (Waters), which 
also were used to process the data. BFH C18 1.7 μm (2.1 x 100 mm) column (Waters) was used 
for the chromatographic separation and maintained at 40°C. The peaks of interest were 
dereplicated using Bovine Metabolome Database, Bovine Rumen Metabolome Database, 
Carotenoids Database, CSF Metabolome Database, DrugBank, E. coli Metabolome Database, 
Fecal Metabolome Database, Golm Metabolome Database, Human Metabolome Database, 
LipidMAPS, Marine Drugs, Nature Chemical Biology, Nature Chemistry, Nature 
Communications, Peptides, Saliva Metabolome Database, Serum Metabolome Database, 
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6 Results  
6.1 Bioactivity of initial cultures 
The initial solid cultures and liquid micro-cultures of the eight fungal isolates without 
epigenetic modifiers were tested for antibacterial activity against the five pathogenic bacteria 
E. coli, P. aeruginosa, S. aureus, E. faecalis and S. agalactiae. Of the solid cultures only TS7 
were found active in the antibacterial agar plug assay, exhibiting activity against E. faecalis 
and S. agalactiae (Appendix 2). In the antibacterial screening of the liquid micro-culture 
supernatants and in the antibacterial agar disc diffusion assay none of the fungal isolates 
exhibited any activity. The liquid micro-culture supernatants were also tested for protease 
activity, in which 008cD1.1 in M6 and M6 LPS medium exhibited activity. On the basis of these 
results TS7 and 008cD1.1 were selected for further cultivation together with TRa3160C, which 
were of special interest for my advisors. 
6.2 Effects of epigenetic modifiers on fungal growth pattern 
The growth of Digitatispora marina (008cD1.1), Typhula sp. (TRa3160C) and Acremonium sp. 
(TS7) were inspected after 22 and 25 days of incubation on solid medium with the epigenetic 
modifiers 5-azacytidine, SBHA and nicotinamide.  
6.2.1 Solid cultures of Digitatispora marina (008cD1.1) 
Digitatispora marina plates were not full-grown after 3 weeks of cultivation (figure 15) and 
grew slower than the two other fungi. No clear difference in growth pattern were observed 
by the application of different epigenetic modifiers on neither M6 or M6 LPS agar, and the 
growth did not seem to be much affected by their application compared to control cultures, 
not added epigenetic modifiers. 
 
Figure 15 - Growth of Digitatispora marina spotted at three locations on each plate of M6 and M6 LPS agar with 
epigenetic modifiers 5-azacytidine, SBHA and nicotinamide after 22 days of incubation. 
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6.2.2 Solid cultures of Typhula sp. (TRa3160C) 
Typhula sp. grew significantly better on corn meal agar (CMA) compared to Ascophyllum 
nodosum agar (ANA) and were full-grown on CMA plates after 3 weeks of cultivation (figure 
16), while only forming thin treads of mycelia on ANA at the same point of cultivation (figure 
17). Typhula sp. exhibited visible changes of growth pattern on CMA in response to different 
epigenetic modifiers.  
Addition of 5-azacytidine (figure 16 A) and nicotinamide (figure 16 D) both separately and 
conjointly (figure 16 C) seemed to have the most similar growth pattern to the control cultures 
(figure 16 F) with dense, thin mycelia evenly dispersed all over the plate with some growth on 
top of the plugs as well. Cultures only added SBHA (figure 16 E) also formed dense, thin 
mycelia but exhibited in addition more growth on top of the agar and had denser growth near 
the plugs. Culture added SBHA in addition to 5-azacytide and nicotinamide, both separately 
and combined (figure 16 B, G and H), exhibited similar growth pattern differing both from 
cultures only added SBHA and cultures with 5-azacytidine and nicotinamide without SBHA. In 
these cultures Typhula sp. grew thicker mycelia with denser growth near plugs and not as 
evenly dispersed growth over the whole plates as seen in figure 16 A, C, D and F, and with less 
growth on the surface of the agar.  
Growth of Typhula sp. on ANA (figure 17) were quite frail, forming really thin mycelia only 
visible by close examination. 
 
Figure 16 - Growth of Typhula sp. spotted at three locations on each plate of corn meal agar with epigenetic 
modifiers 5-azacytidine, SBHA and nicotinamide after 22 days of incubation. A) 5-azacytidine, B) SBHA + 
nicotinamide, C) 5-azacytidine + nicotinamide, D) nicotinamide, E) SBHA, F) control, G) 5-azacytidine + SBHA, H) 
5-azacytidine + SBHA + nicotinamide.  
A B C D 
E F G H 
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6.2.3 Solid cultures of Acremonium sp. (TS7) 
Acremonium sp. grew well on both M6 and M6 LPS agar in the presence of epigenetic 
modifiers (figure 18) and were almost full-grown after 3 weeks of cultivation. However, visible 
differences in growth pattern in response to different epigenetic modifiers were not observed. 
Figure 17 - Growth of Typhula sp. on Ascophyllum nodosum agar with epigenetic modifiers 5-azacytidine, SBHA 
and nicotinamide after 22 days of incubation. 
Figure 18 - Growth of Acremonium sp. on M6 and M6 agar with epigenetic modifiers 5-azacytidine, SBHA and 
nicotinamide after 22 days of incubation. 
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6.2.4 Liquid cultures of Acremonium sp. (TS7) 
Acremonium sp. cultivated in liquid M6, M6 LPS and ASME media exhibited similar growth 
growing in evenly dispersed threads and lumps out of the agar plugs used for inoculation of 
the cultures. It seemed to grow a bit faster and denser in M6 and M6 LPS compared to ASME 
but displayed the same pigmentation and growth pattern.  
 
Liquid FMAP and FMAP LPS cultures 
initially displayed the same growth pattern 
and culture pigmentation but after a week 
of cultivation started growing in thin 
biofilm looking layers on top of the media 
in some cultures (figure 19). These layers 
were disrupted to assure all fungal material 
were in contact with the media and had 
access to nutrients. DNA samples were 
taken and analysed of all cultures and were 
pure. 
 
After addition of epigenetic modifiers 
cultures added SBHA were observed 
becoming more pigmented than cultures 
not added SBHA (TS7 FMAP null, TS7 FMAP 
AN, TS7 FMAP LPS null and TS7 FMAP LPS AN) (figure 20 A). This pigment seemed to also be 
present in the extracts of the cultures as the extracts had the same pigmentation as the 








Figure 20 - Photographs of the evident pigmentation difference between various TS7 FMAP liquid cultures and 
extracts. A) TS7 FMAP null culture to the left and TS7 FMAP LPS ASN culture to the right. B) TS7 FMAP S extract 
to the left and TS7 FMAP AN extract to the right.  
B A 
Figure 19 - Biofilm looking growth observed in TS7 FMAP 
LPS ASN culture. Pictures taken a few days after attempting 
to disrupt the growth structure. 
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6.3 Bioactivity of solid cultures 
Solid cultures of TS7, 008cD1.1 and TRa3160C with epigenetic modifiers 5-azacytidine, SBHA 
and nicotinamide were tested for antibacterial activity against E. coli, P. aeruginosa, S. aureus, 
E. faecalis and S. agalactiae and antifungal activity against Candida albicans. Only TS7 showed 
activity in the antibacterial assay, results of 008cD1.1 and TRa3160C are therefore not shown. 
TS7 exhibited activity against the three Gram-positive bacteria S. aureus, E. faecalis and S. 
agalactiae, with the strongest activity against S. agalactiae (table 22). The activity against S. 
agalactiae were mostly consistent for all TS7 cultures, regardless of supplemented epigenetic 
modifiers, with the small exception of TS7 M6 LPS AN that also were active against S. 
agalactiae, but were slightly less potent, making an inhibition zone of 17 mm compared to the 
average inhibition zone of 23 mm of the remaining cultures. 
Table 22 – Bioactivity results of solid cultures of TS7 from antibacterial plug assay. E. c: E. coli., P. a: P. 
aeruginosa, S. a: S. aureus, E. f: E. faecalis, S. B: S. agalactiae (Streptococcus type B). (-): Gram-negative 
bacteria, (+): Gram-positive bacteria. Values presented represent diameter of inhibition zone around the fungal 
plug (including the plug of 6 mm) in millimeters. 
Fungus Culture E. c (-) P. a (-) S. a (+) E. f (+) S. B (+) 
Acremonium sp. TS7 M6 null - - 13 11 23 
Acremonium sp. TS7 M6 S - - 13 11 23 
Acremonium sp. TS7 M6 A - - 7 6 24 
Acremonium sp. TS7 M6 N  - - 12 10 22 
Acremonium sp. TS7 M6 SN - - 13 11 23 
Acremonium sp. TS7 M6 AS - - 7 6 25 
Acremonium sp. TS7 M6 AN - - 6 6 24 
Acremonium sp. TS7 M6 ASN - - 7 6 24 
Acremonium sp. TS7 M6 LPS null - - 11 11 22 
Acremonium sp. TS7 M6 LPS S - - 10 10 20 
Acremonium sp. TS7 M6 LPS A - - 6 6 23 
Acremonium sp. TS7 M6 LPS N  - - 11 10 23 
Acremonium sp. TS7 M6 LPS SN - - 12 11 23 
Acremonium sp. TS7 M6 LPS AS - - 6 6 23 
Acremonium sp. TS7 M6 LPS AN - - 6 - 17 
Acremonium sp. TS7 M6 LPS ASN - - 6 - 22 
 
No fungal cultures showed any antifungal activity toward Candida albicans. Despite several 
attempts at modifying the assay for testing antifungal activity of liquid cultures to a solid 
culture format, there were no observed inhibition of Candida albicans growth by the 
antifungal agent Amphotericin B. The antifungal assays of the solid cultures were therefore 
invalidated. 
 
6.4 Extraction yields 
Due to the high similarity in bioactivity between solid TS7 cultures, and the low yield normally 
obtained from extraction of solid cultures, it was decided to combine all 32 remaining solid 
TS7 cultures after bioassays (16 culture conditions in parallels) to perform one extraction. The 
ethyl acetate extraction of these cultures yielded an extract of 90.8 mg dry weight. 
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The liquid cultures of TS7 with epigenetic modifiers were extracted by solid phase extraction 
using Diaion® HP-20, which is the standard extraction protocol used at the Marbio lab. Each 
liquid culture of 250 mL was extracted separately and yielded significantly bigger extracts than 
the ethyl acetate extraction of the solid cultures, with an average extract weight of 589.4 mg.  
 
Table 23 – Extract yield in mg for liquid cultures of TS7 with added epigenetic modifiers and media controls (Ctr). 
 Ctr null S SN SA NA SNA 
M6 326.9 301.1 751.9 362.4 526.2 586.5 454.3 
M6 LPS 663.8 221.3 286.9 395.3 510.0 1255.3 598.0 
FMAP 781.6 607.8 527.2 892.8 612.0 1064.2 1060.1 
FMAP LPS 799.7 545.3 963.7 693.2 706.6 1216.1 989.8 
ASME 313.3 255.4 310.4 169.8 224.2 344.4 310.6 
 
FMAP and FMAP LPS cultures yielded on average the biggest extracts with mean weights of 
792.3 and 844.9, respectively compared to 472.8, 561.5 and 275,4 for M6, M6 LPS and ASME, 
respectively.  
 
6.5 Bioactivity of extracts 
The extracts of both liquid and solid cultures were tested for antibacterial activity against E. 
coli, P. aeruginosa, S. aureus, E. faecalis and S. agalactiae, antibiofilm activity against S. 
epidermidis, antifungal activity against Candida albicans and anticancer activity against the 
human cancer cell lines A2058 (human melanoma), HepG2 (human hepatocellular carcinoma) 
and MCF7 (human breast adenocarcinoma) with the non-cancerous lung fibroblast cell line 
MRC5 as control for normal human cells and toxicity. All extracts were first tested in 
concentration of 50 μg/mL in all assays, which is the standard concentration for screening of 
flash fractions at Marbio. At this concentration all extracts were inactive in all assays, except 
for the solid culture ethyl acetate extract, which were classified as questionable with OD=0.06 
(threshold for activity: <0.05) exhibiting activity against S. agalactiae (Strep .B) (table 24).  
 
Table 24 - Results of antibacterial screening of ethyl acetate extract of solid TS7 M6 and M6 LPS cultures. 
Number represent measured OD. Threshold for activity: 0.05, questionable: 0.09-0.05. E. c: E. coli, P. a: P. 
aeruginosa, S. a: S aureus, E. f: E. faecalis, S.B: S. agalactiace (staphylococci group B). 
 E. c P. a S. a E. f S. B 
50 μM 0.43 0.47 0.30 0.29 0.06 
150 μM 0.36 0.49 0.13 0.10 0.03 
 
It was decided to retest the extract at a higher concentration due to the lack of activity in most 
extracts. This may be due to the complexity of crude extracts that possibly contain 
contradictory compounds inhibiting bioactive compounds, compared to purified fractionated 
samples. The antibacterial and anticancer assays were repeated at 150 μg/mL. At this 
concentration the solid culture ethyl acetate extract was active against Strep. B with OD=0.03 
and exhibited some tendency to activity against S. aureus and E. faecalis as well (table 24), 
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with OD of 0.13 and 0.10, respectively (threshold for classification as questionable: 0.06-0.09). 
The remaining extract did not exhibit activity at increased concentration, therefore only the 
results of the solid culture ethyl acetate extract are presented here. The results of the liquid 
culture extract are in Appendix 2. 
No anticancer activity was observed at increased concentrations in any of the extracts. 
Additional assays were not possible to perform due to the occurrence of the COVID-19 
pandemic resulting in the closing off of university locations, including laboratories, for all 
students and restricted access for most employees.  
 
6.6 Mass spectrometry analysis 
Bioactivity was only observed in the solid cultures and the ethyl acetate extract produced from 
them. The identification of the compound(s) accountable for this activity in these samples was 
the main focus of the MS analysis. Generally, most of the cultures seemed to have the same 
peaks in the MS chromatograms, with some variation in the height of the peaks and the 
strength of the signals of various candidate masses. A common feature in these samples was 
strong responses for the candidate mass 1050.75 m/z RT: 8.72 (predicted mainly to 
C57H105N5O8P2 or C54H99N9O11) (figure 21). The signal of 1050.75 m/z occurred in all solid TS7 
cultures as well as the solid culture extract (table 25). This signal represented the strongest or 
second strongest signal in 12 out of 16 solid cultures and was the third, fourth and seventh 
highest in the remaining 4 cultures, with TS7 M6 LPS AN having the weakest signal with 
1050.75 m/z as the seventh strongest signal. The solid culture extract had 1050.75 m/z as the 
second highest signal.  
 
Figure 21 - Mass spectrometry chromatogram of ethyl acetate extract of all solid TS7 M6 and M6 LPS cultures. The 
red arrow indicated to the peak of 1050.7514 m/z, which represents the second strongest response after 511.3740 
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Table 25 - Mass to charge (m/z), retention time (RT), response, predicted elementary compositions (with 
elements: C, H, N, O, (P) and adduct: +H) and iFIT confidence of prediction, and intensity of response in sample 
(1st: strongest response in sample etc.) of TS7 ethyl acetate extract (EtoAcE) of solid cultures and solid TS7 
cultures with epigenetic modifiers before extraction. 
 m/z RT Response Prediction Response 
rank 
EtoAcE 1050.7514 8.72 1 039 529 C57H105N5O8P2 (97.51%) 2nd 
M6 null 1050.7515 8.54 1 964 987 C57H105N5O8P2 (97.29%) 1st 
M6 S 1050.7516 8.57 1 273 352 C57H105N5O8P2 (99.89%) 1st  
M6 A 1050.7521 8.57 564 278 C57H105N5O8P2 (77.64%) 
C54H99N9O11 (91.96%) 
3rd 
M6 N  1050.7512 8.56 823 205 C57H105N5O8P2 (97.15%) 1st 
M6 SN 1050.7515 8.57 688 899 C57H105N5O8P2 (91.64%) 2nd  
M6 AS 1050.7516 8.58 852 158 C57H105N5O8P2 (84.44%) 2nd  
M6 AN 1050.7527 8.57 1 262 934 C57H105N5O8P2 (59.74%) 
C54H99N9O11 (92.14%) 
1st  
M6 ASN 1050.7521 8.56 1 145 116 C57H105N5O8P2 (24.14%) 
C54H99N9O11 (96.90%) 
1st 
M6 LPS null 1050.7524 8.60 1 336 598 C57H105N5O8P2 (32.08%) 
C54H99N9O11 (96.04%) 
1st 
M6 LPS S 1050.7518 8.62 621 794 C57H105N5O8P2 (81.95%) 
C54H99N9O11 (89.53%) 
3rd  




M6 LPS N  1050.7518 8.62 769 632 C57H105N5O8P2 (89.92%) 2nd  
M6 LPS SN 1050.7516 8.60 865 759 C57H105N5O8P2 (85.02%) 2nd  
M6 LPS AS 1050.7511 8.58 480 776 C57H105N5O8P2 (69.32%) 
C58H101N9O4P2 (10.80%) 
4th  
M6 LPS AN 1050.7523 8.60 421 714 C57H105N5O8P2 (68.05%) 
C54H99N9O11 (78.05%) 
7th  




In 7 out of the 16 solid cultures the elementary composition of C54H99N9O11 were predicted 
more likely than C57H105N5O8P2 (which was the most likely elementary composition of 8 out of 
the 16 solid cultures and the solid culture extract). One culture, M6 LPS A, did not have high 
iFIT confidence for neither C57H105N5O8P2 nor C54H99N9O11. In contrary to C57H105N5O8P2, 
C54H99N9O11 had three hits for molecular structure in PubChem as well as a structure named, 
Emericellipsin A (figure 22), isolated from a closely related fungus to TS7, Emericellopsis 
alkalina (sexual form of Acremonium alkalina), which has been found to exhibit bactericidal 
activity against methicillin resistant S. aureus and vancomycin resistant E. faecalis (Rogozhin 
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Table 26 - Mass to charge (m/z), retention time (RT), response, and intensity of response in sample (1st: 
strongest response in sample etc.) of the extracts of liquid TS7 cultures which contained 1050.75 m/z. 
 m/z RT Response Response rank 
M6 null 1050.7525 8.64 34 567 571st  
M6 S 1050.7516 8.65 19 064 868th  
M6 SN 1050.7533 8.65 19 027 768th  
M6 AS 1050.7526 8.64 10 872 1225th  
M6 AN 1050.7527 8.65 14 664 993rd  
M6 ASN 1050.7520 8.64 15 592 1388th  
M6 LPS null 1050.7526 8.64 63 694 342nd  
M6 LPS S 1050.7521 8.64 67 918 249th  
M6 LPS SN 1050.7532 8,65 28 962 551st  
M6 LPS AS 1050.7520 8.64 7 067 981st  
M6 LPS AN 1050.7533 8.64 4 927 1306th   
M6 LPS ASN 1050.7526 8.63 3 686 1624th  
ASME null 1050.7524 8.62 20 659 240th  
ASME S 1050.7521 8.63 20 788 271st  
ASME SN 1050.7533 8.62 4 804 454th  
ASME AS 1050.7515 8.61 12 466 338th  
ASME AN 1050.7508 8.62 9 968 330th  
ASME ASN 1050.7530 8.62 4 203  550th  
FMAP LPS AS 1050.7555 8.64 2 904 4621st  
 
The signal of 1050.75 m/z with RT of approximately 8.60 were also observed in all liquid 
culture extracts of TS7 M6, M6 LPS and ASME and one TS7 FMAP LPS extract; TS7 FMAP LPS 
AS, however with significantly weaker responses than in the solid cultures (table 26). 
Responses of 1050.75 m/z varied from 2 904 to 67 918 in the liquid culture extracts compared 
to 421 714 to 1 964 987 in the solid culture extracts. 
 
Figure 22 - Structure of Emericellipsin A (C54H99N9O11, 1049.76 Da.) (Rogozhin et al., 2018). 
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7 Discussion 
 
Marine filamentous fungi were investigated in three rounds of cultivation and bioactivity 
testing. The initial and preliminary cultivation included the eight fungal isolates Digitatispora 
marina (008cD1.1), Amylocarpus encephaloides (018bII1.1), Tolypocladium inflatum 
(010cU1.3), Calycina marina (TRa3180AII.4), Typhula sp. (TRa3160C), Mytilinidion sp. 
(M16HEL1360D1-10.1), Lulworthia sp. (TRa3202.III.1), and Acremonium sp. (TS7). These were 
all cultivated in both solid and liquid M6, M6 LPS, FMAP, and FMAP LPS media and tested for 
antibacterial and protease activity. The three most interesting fungi from these screening, 
Digitatispora marina (008cD1.1), Typhula sp. (TRa3160C), and Acremonium sp. (TS7), were 
subjected to another round of cultivation on solid media supplemented with epigenetic 
modifiers: DNA methyltransferase inhibitor (DNMT) 5-azacytidine, histone deacetylase 
inhibitor (HDAC) SBHA and sirtuin inhibitor nicotinamide. These cultures were screened for 
antibacterial and antifungal activity, in which only TS7 exhibited activity. All TS7 cultures were 
then combined for a liquid-liquid extraction using ethyl acetate. Lastly, TS7 was cultivated in 
liquid M6, M6 LPS, FMAP, FMAP LPS and ASME media with a reduced number of combinations 
of epigenetic modifiers (S, AS, SN, AN and ASN) to ease the workload. The cultures with 5-
azacytidine (A) and nicotinamide (N) added singly were excluded because the MS analysis of 
the solid cultures added these epigenetic modifiers showed the flattest peaks and seemingly 
lowest production of compounds. The liquid cultures were extracted by solid phase extraction 
using Diaion® HP-20 and screened for antibacterial, antibiofilm, antifungal and anticancer 
activity. Only antibacterial activity was observed, exhibited by the ethyl acetate extract of the 
solid cultures. All extracts and solid cultures with epigenetic modifiers were analyzed using 
mass spectrometry (MS).  
The aim of this thesis was to identify if the application of small molecule inhibitors would have 
an impact on the secondary metabolites produced by the selected fungi, and if bioactive 
secondary metabolites could be identified through this approach. If so, develop a method for 
the implementing the of supplementation of these inhibitors to fungal cultures as part of the 
biodiscovery pipeline at Marbio.    
These small molecule inhibitors serve as epigenetic modifiers, inhibiting the transcription 
repressive activity of epigenetic enzymes DNMTs, HDACs and sirtuins. These enzymes repress 
transcription by adding or removing epigenetic markers on DNA or histone resulting in denser 
packing of DNA to the inaccessible conformation, heterochromatin. BGCs in this conformation 
are so called silent. By inhibiting this activity more BGCs remain in the euchromatin 
conformation, accessible for transcription. Epigenetic modifiers were employed to fungal 
cultures to investigate if their application could be implied as an extension of the OSMAC 
approach. And by this establish a method for studying the metabolic potential of fungi at 
Marbio that is more efficient in awakening silent BGCs than OSMAC alone. As the application 
of epigenetic modifiers is a fairly straight forward strategy and does not require genetic 
manipulation of fungi, I imagine this could be applied as a method for early investigation of 
fungal secondary metabolite production.  
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7.1 Bioactivity observed from the fungal cultures  
The results of the first application of epigenetic modifiers to solid cultures of TS7, which had 
already been found active to a selection of bacterial strains, showed rather unsatisfactory 
results. All TS7 cultures, regardless of epigenetic modifiers supplemented had similar 
bioactivities and MS chromatograms to control cultures, and only minor differences in the 
intensity of MS signals were observed. This indicated that the same biosynthetic gene clusters 
might have been active in all cultures, producing the same metabolomes and secondary 
metabolites, but in different quantities. The same were observed for 008cD1.1 and TRa3160C 
which were uniformly inactive in all assays and had rather indistinguishable MS 
chromatograms.  
The cultivation of fungi with epigenetic modifiers on solid media, were based on the initial 
cultivations without epigenetic modifiers. Fungi were cultured for 30 days at 10°C on solid 
media added 50 μM 5-azacytidine, 500 μM SBHA and/or 50 μM nicotinamide. These 
concentrations were used based on the reporting of 5-azacytidine being applied at 0.1 μM to 
10 mM to fungal cultures and showing effective induction of BGCs from 10 μM (Asai, 
Yamamoto, Chung, et al., 2012; Chen et al., 2016; González-Menéndez et al., 2014; Igboeli et 
al., 2019; J. Sun et al., 2012; Williams et al., 2008; Yakasai et al., 2011). SBHA have also been 
applied in the range of 0.1 μM to 10 mM but have mostly been reported effective at 500 μM 
to 1 mM (Asai et al., 2011; Asai, Chung, Sakurai, Ozeki, et al., 2012; Asai, Luo, Obara, Taniguchi, 
et al., 2012; Asai, Yamamoto, & Oshima, 2012; J. Sun et al., 2012; Yakasai et al., 2011). Lastly, 
nicotinamide has been reported applied at 10-500 μM with the most significantly effects on 
secondary metabolism at 50 and 100 μM (Asai et al., 2016; Asai, Morita, Shirata, Taniguchi, et 
al., 2012; El-Hawary et al., 2018). 
Based on the results from the analysis of the solid cultures, it was decided to attempt to do 
further cultivating with epigenetic modifiers. As the majority of studies reporting successful 
induction of secondary metabolism and identification of novel secondary metabolites have 
cultivated fungi in liquid media, it was decided to try and cultivate TS7 in this way as well. Due 
to time constrains and TS7 growing notably faster than the other fungi in this study in the 
previous cultivations it was decided to shorten the incubation time. Several studies have 
reported successful induction of fungal secondary metabolism after one to two weeks of 
cultivation, including one study of cultivating the marine fungus Asteromyces cruciatus for 14 
days (Igboeli et al., 2019). It was therefore decided to test if cultivation of TS7 for 16 days 
would be sufficient.  
Epigenetic modifiers SBHA, 5-azacytidine and nicotinamide were added at day 9 of cultivation 
at concentrations of 500 μM, 50 μM and 50 μM, respectively. Secondary metabolism is 
generally repressed during the initial, logarithmic growth and gets derepressed during the 
stationary growth phase (Malik, 1980). As fungi had been observed to grow slower in the 
presence of epigenetic modifiers in the solid cultures, epigenetic modifiers were therefore 
tried added after the logarithmic growth had ceased at day 13 of incubation. Cultures were 
extracted by solid-phase extraction using Diaion® HP-20 after 16 days of cultivation. However, 
MS chromatograms showed only minor differences in peak height and bioassay results 
showed no activity.  
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7.2 Investigation of active cultures  
Because only solid cultures and the ethyl acetate extract produced from them exhibited 
activity in the bioassays, these samples and the potential compound(s) causing this activity 
were the main focus of the mass spectrometry analysis. Just as the bioactivity results, the MS 
chromatograms for each culture were very similar, with generally the same MS peaks at the 
same retentions times with minor differences in peak intensity. As solid cultures and the ethyl 
extract exhibited the same activity and were fairly potent in its activity against S. agalactiae 
the peak(s) for the active compound(s) should represent a relatively big peak in all samples. A 
common feature in all samples were high responses for the signal of 1050.75 m/z RT: 8.72 
(predicted to C57H105N5O8P2 or C54H99N9O11). The elementary composition of C57H105N5O8P2 
gave no hits for molecular structure in any of the available databases. However, C54H99N9O11 
had three hits in PubChem of potential structures in addition to a fourth potential molecular 
structure (Rogozhin et al., 2018). In this study they found a novel lipopeptide, Emericellipsin A 
(C54H99N9O11) isolated from Emericellopsis alkalina (sexual form of Acremonium alkalina) to 
exhibit bactericidal activity against methicillin resistant S. aureus and vancomycin resistant E. 
faecalis which both are classified as pathogens of high priority for antibiotic research by WHO 
(Rogozhin et al., 2018; WHO, 2017). This could correspond with my finding of the solid TS7 
cultures to inhibit growth of S. aureus and E. faecalis in the agar plug diffusion assay, although 
I did not screen for activity against the resistant strains of these bacteria. 
In the ethyl acetate extract and eight out of the 16 solid cultures the signal of 1050.75 m/z 
were predicted to C57H105N5O8P2 with highest iFIT confidence, and in seven other cultures it 
was predicted to C54H99N9O11 with the highest iFIT confidence. However, the presence of two 
phosphor atoms in one compound is quite rare, making the elementary composition of 
C54H99N9O11 more probable.  
The number of amino acids of 1050.75 m/z predicted based of the fragmentation pattern 
observed in the MS/MS spectra of the ethyl acetate extract, exceeded the maximum number 
of amino acids of the elementary composition C57H105N5O8P2. An additional indication that 
C54H99N9O11 is a more likely elementary composition. However, the fragmentation pattern did 
not match the amino acids constituting Emericellipsin A. This indicates that the observed 
compound might not be Emericellipsin A, but perhaps a compound of similar molecular 
weight. 
TS7 was previous to this thesis whole genome sequenced and annotated by Ph.D. student Ole 
Christian Hagestad and identified BGCs were subject to homology search to identify similar 
BGCs and possible products for the BGCs of TS7. Among the identified homologues were the 
leucinostatin A (C62H111N11O13, 1218.6 Da) BGC from Purpureocillium lilacinum (G. Wang et al., 
2016). This BGC were found to be 15% similar to a PKS BGC and 35% similar to a NRPS BGC in 
TS7. Both these clusters are located on contig ends, and as the compound of 1050.75 m/z is 
probably a lipopeptide (hybrid compound), such as Emericellipsin A, these two BGCs might be 
the two halves of the one BGC producing the compound of 1050.75 m/z. This cluster could 
probably be identified using real time PCR to sequence the transcriptome of the TS7 samples 
with strong responses for 1050.75 m/z. If Emericellopsis alkalina were whole genome 
sequenced, the genomes of Acremonium sp. TS7 and Emericellopsis alkalina could be analyzed 
by a homology search to identify the BGC producing Emericellipsin A in Emericellopsis alkalina 
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and the homologous cluster in TS7. This analysis would also confirm if the compound observed 
in this thesis is Emericellipsin A or a similar compound of the same molecular weight, by 
comparison of the genes constituting the two clusters. 
 
7.3 Induced colony morphological changes and pigmentation 
It seems that the solid TS7 M6 and TS7 M6 LPS cultures, and their extract, which were the only 
cultures showing activity, did not exhibit this activity because of the addition of epigenetic 
modifiers. The antibacterial activity observed in solid cultures were also present in samples 
without added epigenetic inhibitors, which showed the same potency as the other cultures.  
Highlighted by the fact that all cultures of TS7 in M6 media with and without LPS exhibited 
activity in the antibacterial plug assay with no significant difference in the inhibition between 
the different combinations of epigenetic modifiers and the control cultures, these results lead 
me to believe the BGCs responsible of producing the secondary metabolites possessing this 
activity are not silent. The attempt of activating silent BGCs for the purpose of identifying 
novel compound was not successful. However, the epigenetic modifiers had some visible 
effects on the growth of both TS7 and TRa3160C, resulting in increased pigmentation of liquid 
TS7 cultures in FMAP and FMAP LPS media added SBHA and altered colony morphology of 
TRa3160C on corn meal agar added SBHA. Although the pigment in FMAP and FMAP LPS 
cultures was not found in the MS chromatogram, and TRa3160C was not found to exhibit 
activity in the performed bioassays. These changes to the culture appearances indicate that 
the epigenetic modifiers still had some effects on the metabolome of these fungi.  
 
7.4 Cultivation optimization measures for increased efficacy of 
epigenetic modifiers 
7.4.1 Amount and time of addition of epigenetic modifiers  
Solid cultivation was preformed first because fungi are known to generally produce more 
secondary metabolites on solid media compared to liquid media (VanderMolen et al., 2013). 
However, solid cultivation introduces some limitations to the application of epigenetic 
modifiers as these must be added while the medium is still liquid and must therefore be added 
at the start of incubation and cannot be replenished at a later time during the cultivation. In 
addition, compounds are generally harder to extract from solid cultures and the extraction 
yield are thus often significantly lower (VanderMolen et al., 2013).  These limitation might be 
the reasons most researches choose liquid cultivation when applying epigenetic modifiers to 
fungal cultures (Akone et al., 2016; Asai et al., 2011; Asai, Luo, Obara, Taniguchi, et al., 2012; 
Asai, Yamamoto, & Oshima, 2012; Asai et al., 2013, 2016; El-Hawary et al., 2018; Igboeli et al., 
2019; J. Sun et al., 2012; Williams et al., 2008; Yakasai et al., 2011; Yang et al., 2014). Only one 
study of the application of epigenetic modifiers to solid cultures were found, in which the 
marine derived fungus Cochliobolus lunatus was cultivated with 5-azacytidine (Chen et al., 
2016). Liquid cultivation was therefore also applied to utilize the possibility to add the 
epigenetic modifiers at a later time, and let the fungi grow undisturbed for the initial part of 
cultivation.  
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The observed indistinguishableness of both solid and liquid cultures might be due to addition 
of too low concentration of epigenetic modifiers, the modifiers being degraded during the 
cultivation or the epigenetic modifiers having no or small effect on the fungi tested in this 
thesis. Although all three epigenetic modifiers were applied at concentrations found effective 
in previous studies (Asai et al., 2016; Asai, Yamamoto, Chung, et al., 2012; Chen et al., 2016), 
these might be too low for these specific fungi. 5-azacytidine is an irreversible inhibitor of its 
target, DNA methyltransferase (Gnyszka et al., 2013). However, SBHA and nicotinamide are 
not. Nicotinamide is a physiological inhibitor of sirtuins and must be maintained at high 
concentrations to block the effect of sirtuins. The activity of histone deacetyl inhibitor SBHA 
is also reversible, as SBHA lack the aromatic ring the irreversible HDACs SAHA and TSA uses to 
lock themselves in the catalytic pocket of HDACs (Seto & Yoshida, 2014). It might therefore 
have been advantageable, at least for the liquid cultures, to apply the modifiers several times 
during the cultivation to sustain the concentration of the modifiers at an effective level, and 
possibly increase the amounts added.  
Although epigenetic modifiers were found to modify the pigmentation of liquid TS7 cultures 
and colony morphology of solid TRa3160C, I did expect more evident changes to the 
metabolome of the cultures. It could be the case that the epigenetic modifiers applied in this 
thesis are suboptimal for the fungi investigated. Despite SBHA seemingly being the inducer of 
the changes observed in the liquid TS7 cultures and solid TRa3160C cultures, it could possibly 
yield even more potent effects. SAHA which is also a class I and II HDAC inhibitor like SBHA, 
has more reported cases of successful activation of silent BGCs. Still, SBHA were selected for 
application over SAHA in this thesis, as SAHA costs about four times as much as SBHA and is 
significantly more toxic. SBHA and SAHA inhibit HDAC by the same mechanism, except for the 
lock in place ability of SAHA due to its aromatic ring. However, SAHA is classified as causing 
germ cell mutagenicity and reproductive toxicity while SBHA is considered non-hazardous 
(Sigma-Aldrich, 2019c, 2019f). As the toxic effects of SAHA are directly related to its ability, 
the classification of SAHA as more hazardous could indicate the higher potency and efficacy 
of SAHA. 
7.4.2 Cultivation length 
The liquid cultures not showing any activity when exposed to epigenetic modifiers might also 
be due to too short cultivation time. Although several studies reported isolating novel 
compounds after only one or two weeks, some studies reported cultivating the fungal strains 
for four weeks before extracting (Asai, Luo, Obara, Taniguchi, et al., 2012; Chen et al., 2016; 
El-Hawary et al., 2018). Despite the rapid growth observed by TS7 in the liquid cultures, it 
might have been wise to continue the cultivation for two additional weeks to obtain a higher 
yield of secondary metabolites as the secondary metabolism is  most active in the stationary 
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7.4.3 Time of extraction 
Solid cultures with 5-azazcytidine (A, AS, AN and ASN) were started three days before the 
cultures only added SBHA and nicotinamide (null, S, N, SN). Still, all cultures were screened for 
antibacterial activity precisely 30 days after incubation start.  In the ethyl acetate extraction, 
all solid cultures were combined and extracted simultaneously at 46 days after cultivation 
start of the culture null, S, N, and SN and 49 days after cultivation start of the cultures A, AS, 
AN and ASN. The extraction was not performed immediately after activity testing because the 
workflow of the thesis was not predefined and the methods and analyzes performed were 
determined based on the retrieved results. However, the delay before extracting the cultures 
might have affected the extraction yield of the solid cultures as reported by (Chen et al., 2016) 
after cultivating the marine-derived fungus C. lunatus on solid medium with 5-azacytidine. 
They studied the optimal extraction time for obtaining the highest extract yield by extracting 
the cultures after 20, 22, 24, 26, 28, 30, 32 and 35 days and found the optimal days were 26, 
28 and 30 days, with yields decreasing after 32 days (Chen et al., 2016). As the solid cultures 
of TS7 were first extracted after 46 and 49 days, the obtained extract might therefore not 
represent the actual activity of the cultures, as observed in the antibacterial plug assay 
performed after 30 days of cultivation, as active compounds might have been degraded in the 
time after activity testing before extraction. The MS analysis of the solid cultures was 
performed one week before the extraction (40 and 43 days after incubation start).  
The solid cultures were extracted using a micro ethyl acetate plug extraction method before 
MS analysis which should have led to the extraction of same type of compounds as extracted 
from all the solid cultures combined. The delay before extracting the cultures may have led to 
partial degradation of the potential lipopeptide representing 1050.75 m/z. Amino acids in 
peptide are targeted by numerous degradation pathways including deamination, hydrolysis 
and oxidation (Bell, 1997). If this potential lipopeptide have been exposed to degradation, the 
observed activity in the ethyl acetate extract might therefore be weaker that its true potential. 
7.4.4 Extraction procedure 
Ethyl acetate extraction was selected as the extraction method for the solid cultures as the 
standard extraction method at Marbio, solid phase extraction using Diaion® HP-20, was not 
applicable to solid cultures. Ethyl acetate extraction is routinely used for extraction of plugs 
from solid cultures at Marbio, and seems to be the preferred organic solvent for liquid-liquid 
extraction as the great majority of studies of epigenetic modifiers applied to fungal cultures 
to induce secondary metabolite production reported extracting the cultures using ethyl 
acetate (Akone et al., 2016; Asai et al., 2011, 2013, 2016; Asai, Luo, Obara, Taniguchi, et al., 
2012; Asai, Yamamoto, & Oshima, 2012; Chen et al., 2016; El-Hawary et al., 2018; Igboeli et 
al., 2019; Yakasai et al., 2011; Yang et al., 2014).  
Only cultures extracted by liquid-liquid extraction (LLE) using ethyl acetate exhibited activity 
while all extracts prepared by solid phase extraction (SPE) using Diaion HP-20 resin beads were 
inactive. Although the liquid cultures extracted by SPE yielded significantly bigger extracts, the 
media controls, which were also extracted by SPE, yielded as big extracts. Indicating that 
although SPE produced significantly bigger extract, a large portion of the weight seems to be 
medium components. Regardless of the extraction method, solid cultures are known to 
generally have lower extraction yields than liquid cultures (VanderMolen et al., 2013).  
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Although extraction using Diaion HP-20 is known to be effective, this method might be inferior 
to ethyl acetate extraction in this case.  The liquid cultures that were extracted were fairly 
small (only 250 mL) and considering the “target compound” often constitutes less than 1% of 
the crude extract weight (Koehn & Carter, 2005), one could argue that the chances of 
detecting more compounds would have been greater if bigger cultures were extracted. 
Nevertheless, I believe the extraction methods applied had huge impact on the compound 
composition in the crude extracts. The SPE seems to extract a lot of unnecessary compounds 
producing noisy extracts while the ethyl acetate extract seemed purer. To properly identify 
which of LLE and SPE is best for extraction of liquid cultures for the purpose of extracting and 
identifying secondary metabolites, parallel liquid cultures should be cultivated and subjected 
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8 Conclusion  
 
By the observed change in pigmentation of liquid TS7 cultures and altered colony morphology 
of solid TRa3160c cultures, both by HDAC inhibitor SBHA, it appears this type of epigenetic 
modifies are able to alter gene expression in these fungi. Still, the treatment of marine fungi 
with DNMT inhibitor 5-azacytidine, HDAC inhibitor SBHA and sirtuin inhibitor did not result in 
evident changes in secondary metabolite production. Antibacterial activity against S. 
agalactiae and partial activity against S. aureus and E. faecalis were still observed in TS7 
cultures, but seemingly regardless of addition of epigenetic modifiers. As SBHA were able to 
induce visible changes in the fungal cultures, the lack of effects to secondary metabolism could 
be due to too low concentration of the applied epigenetic modifiers, or in the case of the liquid 
cultures, too short cultivation time.  
 
For further studies of application of epigenetic modifiers to TS7 or other filamentous fungi I 
believe that the application of SAHA instead of SBHA should be attempted as SAHA is 
acknowledged as a more potent HDAC inhibitor due to its irreversible inhibiting activity. 
Because SBHA was here proven to affect the appearance of TS7 and TRa3160c cultures, 
indicating changes in gene expression, SAHA could be effective as well. A number of different 
concentrations of the applied epigenetic modifiers should also be applied as it seems that the 
necessary concentration for effective DNMT and HDAC inhibition differs between fungi. And 
lastly, different cultivation lengths and extraction timings should be tested out to identify the 
optimal timing for the specific fungus. The transcriptomes of the cultures should also be 
analyzed by RT-PCR to identify which BGCs are active and quantify the rate of their 
transcription. 
If these measure does not yield an increased number of identified secondary metabolites from 
the BGCs of the fungi investigated other strategies such as promoter exchange for all genes in 
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Appendix 
Appendix 1 – Culture media 
 
Table 27 – Products and equipment’s used for the making of fungal culture media  
Glucose  D9434 Sigma-Aldrich (Missouri, USA) 
Fish filet powder Polarsnacks Tørrfiskfilet Arctic Taste AS 
Peptone from casein, 
enzymatic digest  
82303 Sigma-Aldrich (Missouri, USA) 
Sea salts S9883 Sigma-Aldrich (Missouri, USA) 
MilliQ H2O MilliQ Gradient A10 Merck Millipore KGaA, 
Germany  
Agarose A1296  
 
Sigma-Aldrich (Missouri, USA) 
Difco Marine Broth  279110 Becton, Dickinson and 
Company, New Jersey, USA  
Filtrated sea water 5 μm pore size, ceramic 
membrane filter 0.2 μm, 
UV filter  
Norwegian College of Fishery 
Science, UiT (Norway) 




Malt Extract  70167 Sigma-Aldrich (Missouri, USA) 
 
M6 medium 
5 g glucose, 0.5 g fish filet powder, 1 g peptone, 40 g sea salts, and 1 L MilliQ H2O (15 g agar) 
(0.6 ng/mL LPS) 
 
FMAP medium 
15 g Difco Marine Broth, 5 g peptone, 300 mL filtrated sea water, and 700 mL MilliQ H2O (15 
g agar) (0.6 ng/mL LPS) 
 
Ascophyllum nodosum agar 
10 g Ascophyllum nodosum powder, 15 g agar, 500 mL filtrated sea water and 500 mL MilliQ 
H2O 
 
Corn meal agar 
17 g corn meal agar, 500 filtrated sea water and 500 mL MilliQ H2O 
 
ASME medium 
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Appendix 2 – Bioassay results 
 
Table 28 - Results of antibacterial agar plug diffusion assay of initial solid fungal culture without added epigenetic 
modifiers. Numbers represent size of inhibition zones in millimeters. 
Fungus Medium E. c (-) P. a (-) S. a (+) E. f (+) S. B (+) 
Digitatispora marina FMAP - - - - - 
FMAP LPS - - - - - 
M6  - - - - - 
M6 LPS - - - - - 
Amylocarpus encephaloides FMAP - - - - - 
FMAP LPS - - - - - 
M6  - - - - - 
M6 LPS - - - - - 
Tolypocladium inflatum FMAP - - - - - 
FMAP LPS - - - - - 
M6  - - - - - 
M6 LPS - - - - - 
Calycina marina FMAP - - - - - 
FMAP LPS - - - - - 
M6  - - - - - 
M6 LPS - - - - - 
Typhula sp. FMAP - - - - - 
FMAP LPS - - - - - 
M6  - - - - - 
M6 LPS - - - - - 
Mytilinidion sp. FMAP - - - - - 
FMAP LPS - - - - - 
M6  - - - - - 
M6 LPS - - - - - 
Lulworthia sp. FMAP - - - - - 
FMAP LPS - - - - - 
M6  - - - - - 
M6 LPS - - - - - 
Acremonium sp. FMAP - - - - - 
FMAP LPS - - - 14 15 
M6  - - - 11 23 
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Table 29 - Protease activity results. Numbers represent maximum slope of the enzymatic reaction for each 
sample. Threshold for activity: > 0.0005 
 FMAP FMAP LPS M6  M6 LPS 
008cD1.1 0.00001 0.00001 0.00059 0.00073 
018bII1.1 - - - - 
010cU1.3 - 0.00001 0.00001 0.00005 
TRa3180AII.4 0.00001 0.00001 0.00001 - 
TRa3160C 000001 - - - 
M16HEL1360D1-10.1 - - - - 
TRa3202.III.1 0.00001 0.00001 - - 





Table 30 – Results of antifungal activity against Candida albicans of TS7 extracts, EtoAcE: ethyl acetate extract. 
Numbers represent measured OD. Threshold for activity: < 0.05, questionable: 0.05 – 0.09. 
 Ctr null S SN SA NA SNA 
M6 0.268 0.255 0.229 0.234 0.206 0.228 0.192 
M6 LPS 0.259 0.261 0.257 0.229 0.221 0.228 0.240 
FMAP 0.288 0.205 0.272 0.229 0.252 0.218 0.211 
FMAP LPS 0.270 0.247 0.237 0.235 0.222 0.202 0.201 
ASME 0.259 0.241 0.239 0.248 0.249 0.219 0.210 





Table 31 - Results of antibiofilm activity of extracts, EtoAcE: ethyl acetate extract.  Number represent percentage 
survival of cells compared to growth control. Threshold for activity: < 30 % of growth control, questionable 30-40% 
of growth control. 
 Ctr null S SN SA NA SNA 
M6  135.3   134.9   130.6   115.9   113.5   112.6   111.3  
M6 LPS  119.3   131.3   90.6   118.7   110.3   101.0   109.3  
FMAP  116.6   121.2   109.3   105.5   103.6   94.2   97.2  
FMAP LPS  120.2   118.5   111.5   115.5   109.8   115.3   110.9  
ASME  124.0   118.6   104.0   109.6   111.6   110.4   110.8  
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Table 32 - Results of antibacterial screening of liquid culture extracts at 50 μM, EtoAcE: ethyl acetate extract. 



















  Ctr null S SN SA NA SNA 
E. coli M6 0.641 0.572 0.579 0.545 0.559 0.563 0.537 
E. coli M6 LPS 0.652 0.546 0.620 0.451 0.515 0.532 0.443 
E. coli FMAP 0.567 0.549 0.551 0.564 0.560 0.533 0.532 
E. coli FMAP LPS 0.560 0.509 0.489 0.476 0.511 0.555 0.586 
E. coli ASME 0.469 0.548 0.498 0.454 0.487 0.514 0.493 
P. aeruginosa M6 0.550 0.547 0.651 0.669 0.595 0.652 0.606 
P. aeruginosa M6 LPS 0.570 0.566 0.576 0.640 0.628 0.787 0.660 
P. aeruginosa FMAP 0.559 0.620 0.565 0.645 0.599 0.633 0.504 
P. aeruginosa FMAP LPS 0.537 0.615 0.623 0.700 0.647 0.606 0.634 
P. aeruginosa ASME 0.569 0.621 0.689 0.726 0.633 0.633 0.613 
S. aureus M6 0.248 0.315 0.344 0.337 0.344 0.346 0.363 
S. aureus M6 LPS 0.315 0.258 0.343 0.376 0.363 0.375 0.395 
S. aureus FMAP 0.279 0.330 0.397 0.355 0.330 0.386 0.387 
S. aureus FMAP LPS 0.366 0.389 0.415 0.371 0.369 0.349 0.368 
S. aureus ASME 0.354 0.388 0.368 0.374 0.337 0.336 0.397 
E. faecalis  M6 0.397 0.367 0.376 0.355 0.383 0.365 0.395 
E. faecalis  M6 LPS 0.363 0.337 0.381 0.370 0.368 0.391 0.334 
E. faecalis  FMAP 0.376 0.359 0.358 0.360 0.365 0.359 0.380 
E. faecalis  FMAP LPS 0.317 0.353 0.381 0.349 0.352 0.368 0.365 
E. faecalis  ASME 0.346 0.350 0.364 0.350 0.408 0.388 0.372 
Strep. B M6 0.600 0.507 0.566 0.348 0.578 0.317 0.329 
Strep. B M6 LPS 0.560 0.446 0.578 0.577 0.283 0.410 0.308 
Strep. B FMAP 0.519 0.572 0.378 0.530 0.348 0.277 0.343 
Strep. B FMAP LPS 0.501 0.540 0.485 0.475 0.385 0.315 0.328 
Strep. B ASME 0.511 0.577 0.516 0.428 0.270 0.347 0.308 
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Table 33 - Results of antibacterial screening of extracts of 150 μM, EtoAcE: ethyl acetate extract. Numbers 



















  Ctr null S SN SA NA SNA 
E. coli M6 0.499 0.452 0.481 0.463 0.491 0.488 0.441 
E. coli M6 LPS 0.441 0.415 0.432 0.457 0.437 0.468 0.458 
E. coli FMAP 0.398 0.411 0.435 0.452 0.439 0.443 0.456 
E. coli FMAP LPS 0.404 0.406 0.424 0.418 0.444 0.435 0.441 
E. coli ASME 0.368 0.384 0.412 0.396 0.411 0.426 0.425 
P. aeruginosa M6 0.719 0.745 0.783 0.840 0.839 0.845 0.768 
P. aeruginosa M6 LPS 0.719 0.759 0.813 0.779 0.801 0.725 0.842 
P. aeruginosa FMAP 0.618 0.636 0.628 0.774 0.705 0.788 0.793 
P. aeruginosa FMAP LPS 0.595 0.693 0.710 0.724 0.742 0.855 0.750 
P. aeruginosa ASME 0.607 0.571 0.675 0.699 0.641 0.756 0.671 
S. aureus M6 0.286 0.319 0.309 0.325 0.303 0.325 0.286 
S. aureus M6 LPS 0.312 0.319 0.296 0.331 0.271 0.302 0.298 
S. aureus FMAP 0.305 0.269 0.236 0.298 0.258 0.297 0.293 
S. aureus FMAP LPS 0.292 0.288 0.271 0.285 0.266 0.287 0.306 
S. aureus ASME 0.264 0.295 0.294 0.358 0.281 0.328 0.311 
E. faecalis  M6 0.365 0.386 0.367 0.398 0.375 0.351 0.389 
E. faecalis  M6 LPS 0.329 0.357 0.358 0.350 0.340 0.345 0.351 
E. faecalis  FMAP 0.287 0.337 0.348 0.322 0.342 0.339 0.371 
E. faecalis  FMAP LPS 0.289 0.341 0.356 0.342 0.341 0.346 0.375 
E. faecalis  ASME 0.292 0.353 0.340 0.360 0.334 0.358 0.359 
Strep. B M6 0.277 0.289 0.303 0.287 0.285 0.289 0.265 
Strep. B M6 LPS 0.272 0.282 0.288 0.293 0.252 0.245 0.281 
Strep. B FMAP 0.267 0.229 0.247 0.240 0.258 0.270 0.232 
Strep. B FMAP LPS 0.286 0.268 0.323 0.224 0.267 0.264 0.267 
Strep. B ASME 0.266 0.268 0.282 0.239 0.252 0.246 0.255 
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Appendix 3 – Hazards and prices of epigenetic modifiers 
 
Table 34 – Hazards and prices of epigenetic modifiers considered for application.  
 Name Hazards Price Distributor  
DNMT 
inhibitors 
5-azacytidine Acute toxicity, oral 
Carcinogenicity 




RG-108 Acute toxicity, oral 
Acute aquatic toxicity 
€ 953.00 for 200 mg 






SAHA Germ cell 
mutagenicity 
Reproductive toxicity 
€ 282.00 for 25 mg 
(11 280 €/g) 
(Sigma-
Aldrich, 2019c) 




VPA Acute toxicity, oral 
Skin irritation  
Eye irritation   
Reproductive toxicity  










Sirtinol -  € 354.00 for 5 mg 
(70 800 €/g) 
(Sigma-
Aldrich, 2019d) 
Splitomicin -  € 88.20 for 5 mg 
(17 640 €/g) 
(Sigma-
Aldrich, 2019e) 
 
 
 
 
 
 
